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ABSTRACT 
 
JAMES BRADFORD TAYLOR:  The Identification and Evaluation of Likely High-Dose 
Electrophysiology (EP) Procedures at a Large Teaching Hospital 
(Under the direction of Donald L. Fox) 
 
    Fluoroscopy-guided procedures utilizing x-rays may expose patients to radiation doses 
above the threshold for observable radiation-induced effects.  Total fluoroscopy time is often 
available and serves as an indicator of skin dose.  We conducted a retrospective review of 
fluoroscopy times for 225 procedures and identified ablations and biventricular (BIV) device 
implants as likely high-dose procedures, with mean fluoroscopy times of 62+48 minutes and 
51+28 minutes, respectively.  To determine which variables best describe dose, we measured 
skin dose for thirty subjects using radiochromic dosimetry film and found mean doses of 
133+94 rad and 164+176 rad for ablation and BIV procedures, respectively.  We correlated 
dose to fluoroscopy time, weight, body mass index (BMI), the weight and time product, and 
the BMI and time product, and found the latter two correlate best with r-2 values of 0.41 and 
0.36, respectively.  Overweight patients appear to be at the greatest risk of receiving high 
skin doses.  
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INTRODUCTION 
 
Rationale 
    Fluoroscopic procedures, such as barium swallows, which utilize x-rays are primarily 
diagnostic in nature and involve minimal risk to the patients.  However, an increasingly 
larger percentage of procedures, such as angioplasty and vascular stent placement, offer a 
therapeutic benefit to the patient.  Such fluoroscopy-guided interventional procedures often 
provide a less invasive alternative to higher-risk surgical procedures.  Although infrequent, 
severe skin injury can be a resulting side effect from these procedures because they may 
prove to be technically difficult, and can involve total fluoroscopy times in excess of one 
hour or more (Mahesh 2001).   
    The Food and Drug Administration (FDA) has reported that occasionally, severe radiation-
induced burns have occurred in patients undergoing such non-invasive fluoroscopic-guided 
procedures, and has made recommendations for the avoidance of such x-ray-induced skin 
injuries.  In response to the increase in likelihood of radiation-induced injuries from such 
procedures, a September 1994 public health advisory titled Avoidance of Serious X-Ray 
Induced Skin Injuries to Patients During Fluoroscopy-Guided Procedures, was issued by the 
Center for Devices and Radiological Health (CDRH) of the FDA which recommended 
recording pertinent information in the patient’s record allowing for the estimation of 
absorbed dose to the skin (FDA 1994).  One year later, in a follow-up advisory titled 
Recording Information in the Patients Record that Identify the Potential of Serious X-Ray
Induced Skin Injuries Following Fluoroscopy Guided Procedures, the agency provided 
clarification to earlier recommendations and stated that “the purpose of the recommendation 
(1994 advisory) is to encourage identification of those areas of the skin which are irradiated 
at levels of absorbed dose that approach or exceed a threshold for injury” (FDA 1995).  The 
only step most institutions have taken to comply with these advisories is to document total 
fluoroscopy times. 
    More recently in December 2005, the Joint Commission on Accreditation of Healthcare 
Organizations (JCAHO 2006) updated their list of reviewable sentinel events to include high 
patient skin dose from extended fluoroscopy procedures.  A sentinel event is an adverse 
occurrence that involves death or serious injury, or the risk thereof (JCAHO 2006).  The 
update has caused institutions across the country to develop methods and procedures to 
demonstrate compliance with these new requirements; which may include the estimation or 
measurement of skin dose during lengthy fluoroscopy procedures.   
 
Study Purpose 
    The primary objective of this project was to evaluate the radiation dose to adult patients 
undergoing fluoroscopy-guided x-ray procedures in an Electrophysiology (EP) facility at a 
large teaching institution.  Key to this project was the collection and evaluation of data on 
fluoroscopic times, which serve as an indicator of the absorbed dose to the patient.  These 
data helped determine which procedure categories are most likely to produce visible effects 
of radiation exposure to the skin.  Those procedures associated with likely high-doses were 
further evaluated and direct measurements of the actual skin doses were made using a 
radiochromic film that is specifically designed to measure skin dose during fluoroscopically-
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guided procedures.  Supplemental purposes of this project included providing physicians 
with information needed to make informed decisions concerning the management of high-
dose procedures (such as which patients may need follow-up evaluation for skin injury), 
evaluating the need for future assessment of skin doses (such as monitoring for certain high-
risk patients), determining the need for any dose-reduction measures necessary (such as 
which modes of equipment operation deliver the lowest doses), and assisting in compliance 
with FDA Public Health Advisories and JCAHO sentinel event requirements described above 
(such as monitoring high-dose procedures). 
    Specific goals of this project include: 
1. Collecting and evaluating retrospective data on fluoroscopy times for patients 
undergoing various categories of procedures involving x-ray at a large teaching 
hospital. 
2. Determining which categories of procedures are likely to produce observable effects 
to the skin.  
3. Measuring the peak skin dose for thirty-three patients undergoing high-dose 
procedures using a radiochromic film, and evaluating the associated radiation risks. 
4. Evaluating the relationship between peak skin dose, fluoroscopy time, subject weight, 
and subject body mass index (BMI). 
5. Determining which of the above variables may be good predictors of dose for EP 
procedures. 
6. Devising a protocol which provides physicians with an indication as to when skin 
dose may approach a threshold for injury that may indicate when a patient is at risk 
for developing a radiation-induced injury. 
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    The remainder of this paper will explain not only how we set out to achieve these goals, 
but will also provide the reader with background information useful for understanding how 
fluoroscopic x-ray equipment is used for clinical imaging, as well as for understanding the 
science of electrophysiology and the types of abnormalities of the hearts electrical system 
that are effectively treated with the aid of fluoroscopy.  A review of the available literature is 
presented to give the reader a current perspective on fluoroscopy times and radiation doses 
for procedures performed at other EP facilities.  This paper also discusses the experimental 
design and protocols utilized for the retrospective evaluation of fluoroscopy times and for 
measuring skin dose during two selected procedures with possible extended fluoroscopy 
times.  Results of this project are revealed to the reader, and suggestions on the future 
direction for the proper management of high-dose EP procedures are offered.
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BACKGROUND 
 
Radiation Terms 
    There are many terms used to describe radiation.  The Roentgen (R) is a unit of radiation 
exposure, and is a measure of the concentration of free electrons that are produced in air from 
x and gamma rays (Wagner 1996).  One Roentgen is equal to 2.58x10-4 Coulombs (C) kg-1 in 
the International System of Units (Cember 1983).  The intensity of an x-ray beam is 
dependent upon kilovoltage peak (kVp), tube current (mA), the target material in the x-ray 
tube housing, plus any filtration inherent or added to the beam prior to its exposure to the 
patient (Curry 1990).  X-ray beam strength is often described as the exposure rate, which is 
equal to the exposure divided by the time unit (Cember 1983).   
    The two most common interactions between x-rays of the diagnostic energy range and 
atoms in a patient are the photoelectric effect and Compton scattering.  During the 
photoelectric effect, the incident x-ray disappears and the energy is transferred to bound 
electrons which are ejected and have an energy that is equal to the energy of the x-ray minus 
the binding of the electron.  Compton scattering occurs when an x-ray interacts with free 
electrons.  Only part of the energy is transferred to the electron, and the energy of the 
incident x-ray is distributed between the electron as kinetic energy and the remaining 
scattered x-ray.  Electrons ejected by these interactions loose their kinetic energy by colliding 
with other orbital electrons and creating charged particles through a process called ionization 
(Curry 1990).  If a sufficient number of ionization events occur, they can be destructive to 
living tissue.  The quantity of kinetic energy that is absorbed along the path of this ejected 
electron per unit mass is referred to as the absorbed dose.  The rad is the term used to 
describe absorbed dose and is equal to the energy deposition of 100 ergs per gram of 
absorber material.  The SI unit of absorbed dose is the Gray (Gy), and 100 rad = 1 Gy 
(Seeram 1997).  The rad is an indicator of the potential of biological effects from exposure to 
radiation and is the term used throughout this report to describe absorbed dose and the likely 
effects on the skin (Wagner 1996).   
    The relationship between exposure (R) and absorbed dose (rad) depends primarily upon 
the number of electrons present per gram of absorbing material.  One Roentgen of exposure 
corresponds to an energy absorption of 87.8 ergs per gram in air, and to 95 ergs per gram in 
tissue.  Since the absorbed dose in tissue from 1 Roentgen of exposure in air corresponds so 
closely to the adsorbed dose of 1 rad (100 ergs per gram), the two may be considered 
approximately equivalent (Cember 1983).  As other authors have suggested (Seeram 1997, 
Bushberg 2002), it is assumed throughout this paper that 1 Roentgen of measured exposure 
in air equals 1 rad of absorbed dose in tissue. 
 
Biological Effects of Radiation Exposure 
    Biological effects of radiation can be broadly classified as stochastic or nonstochastic.  
Stochastic effects are those in which the probability of the effect increases with dose.  
Examples include radiation-induced cancer and genetic effects.  There is believed to be no 
minimum threshold dose because injury to a few cells could theoretically result in the 
occurrence of the effect (Koenig 2001). 
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    Nonstochastic, or deterministic, effects of radiation exposure require a minimum number 
of cells be adversely involved before the effect can be seen, and such effects are associated 
with a minimum threshold below which the effect can not be detected.  There is a positive 
relationship between increased dose and increased observed damage.  Cataract induction, 
erythema, epilation, and death are examples of deterministic effects (Koenig 2001).  The 
threshold dose is not an absolute number and varies between individuals.  When dose to the 
skin is sufficiently high, repair mechanisms are overwhelmed and the result is cell death and 
tissue breakdown (Wagner 1996).  Wagner et al. have reviewed information on the likely 
deterministic effects of radiation exposures from fluoroscopically-guided procedures, and a 
summary of their research is seen below in Table 1. 
Table 1:  Single delivery (nonfractionated) threshold doses for likely 
deterministic effects of radiation dose (rad) to the skin (Wagner 1996). 
   
 
Effect 
Single-dose  
Threshold (rad) 
 
Onset 
 
Peak 
Early Transient Erythema 200 hours ~24 hours 
Main Erythema 600 ~10 days ~2 weeks 
Temporary Epilation 300 ~3 weeks NA 
Permanent Epilation 700 ~3 weeks NA 
Dry Desquamation 1000 ~4 weeks ~5 weeks 
Moist Desquamation 1500 ~4 weeks ~5 weeks 
Secondary Ulceration 2000 >6 weeks -- 
Late Erythema 1500 ~6-10 weeks -- 
Dermal Necrosis (1st phase) 1800 >10 weeks -- 
Dermal Atrophy (1st phase) 1000 >14 weeks -- 
Dermal Atrophy (2nd phase) 1000 >1 year -- 
Telangiectasia 1200 >1 year -- 
Dermal Necrosis (late phase) >1500? >1 year -- 
 
    It is important to note that the intensity of radiation causing such effects is not felt in any 
way by the patient during the procedure (Wagner 1996).   
 7
    As mentioned earlier, the JCAHO has included high doses from fluoroscopy as a category 
of sentinel event.  Specifically, doses that patients receive are classified as a sentinel event 
when the cumulative dose to a single site exceeds 1500 rad (JCAHO 2006). 
 
The Physics of Fluoroscopic Imaging 
    Fluoroscopy is an imaging technique utilizing radiation to allow for the real-time viewing 
of patient anatomy and physiological function.  Most modern fluoroscopy equipment utilizes 
a CsI-based image intensifier (II) which is coupled to a closed-circuit image-viewing system 
(Bushberg 2002).  The components of an II-based fluoroscopy system are shown below in 
Figure 1. 
Figure 1:  Components of an image intensifier-based fluoroscopy system.
 
 
 
Source: Bushberg 2002 ©Lippincott Williams & Wilkins.  Used with permission. 
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    X-rays first enter the II system by passing through a vacuum window and its supporting 
structure.  They then interact with the input phosphor to produce light.  This light strikes the 
photocathode, and liberates electrons into the electronic lens system, which serves to 
accelerate and focus the electrons onto the output phosphor of the system.  Intermediate 
electrodes also serve to shape and focus the electrons, which interact with the output 
phosphor to produce a green light.  The green light is achieved using a zinc cadmium sulfide 
phosphor that has been doped with silver, and is well matched to the spectral sensitivity of 
many video camera systems used to record the output phosphor image (Bushberg 2002).  
    An image-intensified fluoroscopy system is several thousand times more sensitive to 
radiation than a film-screen radiographic imaging system.  Typically in clinical practice, an II 
requires an incident exposure of 1-5 µR per image or frame.  Most analog video systems 
have only a 30 image per second operation but work using an interlacing fashion; a process 
which divides each frame into two fields and then refreshes each field at a rate of 60 times 
per second.  This virtually eliminates the perception of flicker by the observer which would 
normally be seen at the 30 image per second rate. (Bushberg 2002).  
    A number of enhanced features have been added to fluoroscopy systems over the years, 
one of which is variable frame rate pulsed fluoroscopy.  Unlike continuous fluoroscopy in 
which the x-ray beam is continuously on and typically operates between 0.5 and 5 mA, 
pulsed fluoroscopy produces x-rays in short pulses (Bushberg 2002).  Pulsed systems operate 
at and below 30 pulses second-1, and the pulsed beam is typically of a higher mA than when 
operated in continuous mode.  Since the exposure time is shorter, there is less image blur 
from patient motion and thus image quality is improved with close to or near the same dose 
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rates as continuous fluoroscopy (Bushberg 2002).  This is a distinct advantage in procedures 
involving high object motion such as pulsating vessels or organs such as the heart. 
    The primary variable settings controlling the production and intensity of the x-ray beam 
are kVp and mA.  The kVp determines the energy of the electrons that are accelerated 
towards the tube target material, which in turn determines the energy spectrum of the x-rays 
produced.  Increases in kVp result not only in higher energy x-rays but also an increase in the 
quantity as well.  Beam intensity is proportional to kVp2 (Curry 1990).      
    The number of electrons striking the target depends directly upon the tube current (mA).  
The higher the mA, the more electrons there are to strike the target and as a result more x-
rays are produced (Curry 1990).      
    The exposure rates of modern fluoroscopy systems are controlled automatically with a 
system called the Automatic Brightness Control (ABC).  Its purpose is to maintain the 
brightness of the image displayed on the monitor when thicker and thinner regions of the 
patient are imaged.  It performs this task by controlling the x-ray exposure rate that is 
incident on the input surface of the image intensifier by a sensing process that takes place in 
either the photodiode or video signal (Bushberg 2002). 
    The ABC regulates the kVp and mA in continuous mode, as well as controlling pulse 
width (duration) in pulsed fluoroscopy.  How these variables change as a function of patient 
thickness plays an important role in not only image quality but also patient dose.  The kVp 
and mA generally increase together, but the curves utilized by the equipment manufacturers 
controlling this process can be designed, depending upon the situation, to aggressively 
preserve subject contrast or to give the lowest dose examination possible. 
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Typical Exposure Rates and Variability during Fluoroscopy 
    The CDRH of the FDA regulates the performance of fluoroscopic equipment in the United 
States.  Radiological Health is addressed under Title 21, Chapter I, Subpart J of the Code of 
Federal Regulations.  Part 1020 of Title 21 covers the performance standards for ionizing 
radiation emitting products, and Section 1020.32 specifically addresses fluoroscopic 
equipment.  The following regulations apply to entrance exposure rate limits and the means 
for measuring compliance.    
    Section 1020.32 dictates that the exposure rate of fluoroscopic x-ray equipment is 
measured at 30 cm from the input surface of the image intensifier (21 CRF).  Giles (2002) 
has reported that exposure rates may vary between 0.5 R minute-1 and 10 R minute-1 (1.29 x  
10-4 C kg-1 minute-1 and 2.58 x 10-3 C kg-1 minute-1 respectively).  Such variability is due to 
the mode of equipment operation, movement of the x-ray source during the procedure, and 
age, size, body composition, and specific pathology of the patient (Mahesh 2001).  Many 
modern fluoroscopic x-ray systems, including the equipment used during this study, also 
have an optional high-dose rate mode of operation which allows for exposures as high as 20 
R minute-1 (Giles 2002).   
 
Body Mass Index and its Effect 
    Paisey (2004) and others have looked at patient body mass index (BMI) as it relates to the 
radiation dose received during fluoroscopy.  Body mass index is a number that shows body 
weight that has simply been adjusted for height.  As patient size and BMI increases, the ABS 
of the fluoroscopy equipment will automatically increase the radiation output to allow for 
adequate image creation.   
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    This project evaluated the role that BMI plays in relation to the entrance skin dose 
received.  BMI was calculated for each subject that was monitored using their weight in 
pounds and their height in inches.  The Centers for Disease Control and Prevention (CDC) 
English calculation for adults BMI was utilized and is given below (Centers for Disease 
Control and Prevention 2005):  
BMI = ( 
            Weight in Pounds              
(Height in inches) x (Height in inches)
) x 703 
    The CDC classifies weight status according to BMI, with underweight individuals having 
a BMI below 18.5.  A BMI of 18.5-24.9 is normal, 25-29.9 is overweight, and 30 and above 
is defined as obese (Centers for Disease Control and Prevention 2005).  Although the units 
for BMI are pounds per square inch, they are often omitted.   
 
Backscatter Radiation 
    One commonly measures the entrance skin exposure rate of an x-ray field without using a 
scatter-producing phantom positioned immediately adjacent to the detector.  Such 
measurements do not reflect the contribution to exposure from what is termed backscatter 
radiation.  The entrance skin exposure rate is that rate at the point where the x-ray photons 
enter the patient.  Since over 40% of the entrance skin dose may be from backscattered 
radiation, this must be considered by using the appropriate backscatter radiation correction 
factors whenever one is attempting to estimate skin dose using measured exposure rates 
(Wall 1996).   
    The backscatter factor is defined as the ratio of the entrance skin dose in air at the point 
equal to the surface of the patient where the beam would enter the patient when they are 
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present, to that at the same location when the patient is not present (Annals 2004).  The 
backscatter factor depends upon the x-ray energy spectrum, x-ray beam field size, patient 
thickness, and the distance between the dosimeter used to measure the dose and the surface 
of the skin or phantom (Wall 1996)(Annals 2004).  Typical factors have been described for 
various beam qualities and field sizes by Wall (1996).  The half-value layer (HVL) is the 
amount of material that is needed to reduce the intensity of an x-ray beam by one half and is 
often reported in mm of aluminum (Curry 1990).  Backscatter factors range from 1.26 for a 
10cm x 10cm field size with a HVL of 2.0, to 1.41 for a 30cm x 30 cm field size with a HVL 
of 4.0.  ICRP Publication 93 states typical backscatter factors in the range of 1.2-1.4 (Annals 
2004).  When dose and dose rate measurements are made with an ionization chamber free in 
air for x-ray energy spectra and beam sizes common in diagnostic x-ray, these doses must be 
increased by approximately 20-40% when they are used to describe the entrance skin dose a 
patient may receive (Wall 1996).  It is important to mention that because the radiochromic 
film utilized in this project is placed virtually next to the subjects’ skin, the dose recorded 
includes the contribution from backscatter radiation.   
    As noted earlier, deterministic effects, appearing first as early transient erythema, have 
been observed after absorbed doses to the skin of about 200 rad.  We also know there is great 
variability in the dose rate necessary to achieve acceptable image quality, and that these rates 
may vary by a factor of ten between small and large patients (Wagner 1996).  The typical 
exposure rate for a medium-sized adult patient is roughly 3 R min-1 (Mahesh 2001).  The 
reference level noted by The International Atomic Energy Agency for typical fluoroscopy 
entrance skin exposure rate is 2.5 R minute-1 (IAEA 1996).   
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    As Wall (1996) and others (Annals 2004) have described, a significant contribution to 
entrance skin dose may be received from backscatter radiation.  If one attempts to use 
exposure rates made without a scatter phantom in place or without considering dose 
contribution from backscatter radiation, one may significantly underestimate the dose a 
patient might receive.  Using the typical rates of 2.5-3 R minute-1 as noted by Mahesh and the 
IAEA, and considering that actual skin doses may be increased 20-40% due to backscatter 
radiation, it is apparent that the threshold for observable radiation-induced effects may occur 
on those patients receiving less than one hour of fluoroscopy.  More severe effects can occur 
if the fluoroscopy times are longer and the subsequent doses are larger.  It remains important 
to stress the great variability in exposure rate due to patient size, and that although less likely, 
large patients may exceed a threshold for injury after considerably less fluoroscopy time.  
 
Electrophysiology Lab Fluoroscopy Equipment 
    Except during the period of October 2005 when the EP Lab was closed for renovations, all 
skin dose measurements took place during procedures performed in the EP Lab.  The Lab 
houses a Toshiba Model XTP—8100G cardiac fluoroscopy system with a 9” image 
intensifier.  During October 2005, procedures were performed in either a hospital operating 
room utilizing a portable “c-arm” type fluoroscopic system, or in an adult cardiac 
catheterization lab utilizing Toshiba equipment similar to that found in the EP Lab. 
    Toshiba cardiac systems are calibrated to take advantage of the ability to use lower pulse 
frame rates as described earlier; however the dose per pulse is increased relative to the 30 
pulses/second mode.  The result is higher image quality per image with still lower average 
patient dose at lower pulse rates than compared to using higher pulse rates.   The dose per 
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pulse at the input surface of the II for the 15 pulses/second mode is 5.24µR/frame, which is 
1.5 times the dose per pulse of 3.5 µR/pulse at the 30 pulses/second mode.  All pulse rates 
below 15 pulses/second are at the same dose/pulse as 15, and any pulse rate between 15 and 
30 will have a dose/pulse which decreases linearly from 5.24 µR/pulse maximum down to 
the 3.5 µR/pulse minimum(Bucher 2004).  
    Another operational difference between continuous and pulse fluoroscopy on the Toshiba 
cardiac system is that while continuous fluoroscopy ABC responds by increasing the kVp 
and mA proportionately, pulsed ABC allows independent control of the kVp, mA, and pulse 
width.  This allows the kVp to remain fixed while the mAs product increases in response to 
ABC demand until the 10 R minute-1 limit is reached.  Only when this limit is reached and as 
ABC demand continues to increase, will the kVp begin to rise (in order to increase the 
penetrating ability) and the mAs product begin to decrease, while keeping the entrance skin 
exposure rate under the 10 R minute-1 limit.  This function allows the pulsed mode of 
operation to provide higher image contrast for a longer period of time relative to the 
continuously rising kVp of continuous mode fluoroscopy (Bucher 2004).  Because more x-
rays penetrate the patient at a higher kVp, this mode of automatic control results in higher 
patient doses (Bushberg 2002). 
    It is important for physicists as well as physicians to understand how selecting different 
modes of operation such as pulsed vs. continuous during a procedure affects the dose 
delivered to a patients’ skin and the associated risk.    
    Below is a graphical representation of how the ABC mode of operation for the Toshiba 
unit in the EP Lab functions clinically.  The two variables shown below for four different 
ABC modes of operation (continuous, 30 pulses/second, 15 pulses/second, 7 pulses/second) 
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are entrance skin exposure (ESE) rate (R minute-1) and simulated patient size.  ESE was 
measured 30 cm from the input surface of the II, and patient size was simulated by placing 
increasing thicknesses of aluminum and Lucite material in the x-ray beam. 
    Graphically we can see that only with relatively smaller patients will we achieve dose 
reduction through the utilization of pulsed fluoroscopy.  Overweight and obese patients cause 
the equipment to operate near the maximum output of 10 R minute-1 and they are exposed to 
significantly higher dose rates for all pulsed modes of operation than for continuous mode.  
The physicians taking part in this project were made aware of the information described by 
this figure.  Actual ESE values, phantom thicknesses and ABS modes are found in Appendix 
A.   
Figure 2:  Exposure rates for simulated increases in subject size on a Toshiba model XTP—
8100G in differing modes of operation (continuous and pulsed fluoroscopy). 
0
1
2
3
4
5
6
7
8
9
10
Increasing Patient Size
Ex
po
su
re
 R
at
e 
(R
/m
in
)
Continuous
30 p/s
15 p/s
7 p/s
 
    As described above, one advantage of pulsed fluoroscopy is better image quality during 
those procedures involving motion, such as catheter placement in the heart.  Often times, the 
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image quality of continuous fluoroscopy is adequate, and a physician will use this mode to 
preserve patient dose.  However, a physician may utilize pulsed fluoroscopy when improved 
image quality is necessary, which is most likely to occur for larger patients.  The most 
common mode of pulsed fluoroscopy utilized in the EP Lab is 15 pulses/second.  
 
How the Heart Works 
    The heart consists of four chambers.  Two upper chambers (atria) collect blood returning 
from the body and lungs, while two lower chambers (ventricles) pump blood from the heart 
to the lungs and body.  The upper atria and lower ventricles are separated by valves which, 
when working properly, allow for uni-directional blood flow only.  Large vessels connect to 
the ventricles and are separated by additional heart valves.  These vessels transport blood 
from the heart to the lungs (via the pulmonary artery) and the rest of the body (via the aorta) 
(Minneapolis Heart Institute 2004).   
    The sequence of pumping that is responsible for the continuous flow of blood through the 
heart to the lungs and body and is controlled by a built-in electrical system, which is located 
in the sinus node of the upper right atrium.  Electrical signals move from this sinoatrial node 
through pathways in the atria causing them to beat.  An electrical relay station called the 
atrioventricular (AV) node is located in the middle of the heart, and is where signals pause 
briefly before continuing to the ventricles of the heart causing them to beat.  The electrical 
system in the ventricles is known as the His-Purkinje system, and the start of this system is 
called the His bundle (or the bundle of His) (Minneapolis Heart Institute 2004).  
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Clinical Abnormalities Associated with the Electrical System of the Heart 
    One of the clinical abnormalities associated with improper heart rhythm is arrhythmia.  An 
arrhythmia is an abnormal heart beat which may be too fast (tachycardia), too slow 
(bradycardia), or just simply irregular.  Symptoms of arrhythmia include lightheadedness, 
palpitations, blurred vision, chest pain, shortness of breath, dizziness, fainting, and even 
cardiac arrest.  Atrial tachycardias occur in the upper parts of the heart and include atrial 
flutter and atrial fibrillation (Minneapolis Heart Institute 2004).  Ventricular tachycardias 
occur in the lower parts of the heart.  There are also two common types of tachycardia that 
involve both the upper and lower regions.  One is tachycardia due to reentry in the AV node 
and the other is orthodromic reciprocating tachycardia (ORT).  Bradycardia can be caused by 
sinus node dysfunction or a communication failure between the sinus node and ventricles due 
to dysfunction of the AV node or His-Purkinje system.  (Minneapolis Heart Institute 2004). 
 
Overview of Electrophysiology Procedures 
    Electrophysiology is a branch of cardiology dealing with heart rhythm management.  The 
EP Lab at this institution offers a variety of procedures for testing and treatment of 
arrhythmias, and at the time of this research, there were two full-time Cardiologists with 
special competency in electrophysiology working in the lab.       
    An electrophysiology study (EPS) is a diagnostic test to identify the presence and type of 
arrhythmia.  Catheter ablation (ABL) is a non-surgical treatment for arrhythmia in which 
electrode-containing catheters are introduced through blood vessels into the heart.  Once 
problem areas of the heart are identified, radiofrequency energy waves are sent through the 
catheter where they destroy abnormal electrical pathways which cause the abnormal heart 
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rhythm (Minneapolis Heart Institute 2004). An EPS and ABL are often performed in 
conjunction with one other.   
    Patients with ventricular tachycardia and ventricular fibrillation may be treated by 
inserting an implantable cardioverter defibrillator (ICD).  The ICD is a small, lightweight 
device that monitors heart rhythm and helps return it to normal during arrhythmia.  A 
pacemaker (PM) is another type of small, lightweight electronic device that is implanted in 
the body of patients whose heart is beating too slowly, or whose ventricles do not beat in 
synchronization with each other.  Pacemakers work by keeping the right atrium and 
ventricles working together, a term called AV synchrony, and they are comprised of a pulse 
generator and typically one or two leads.  A lead is the wire that is placed in the heart to 
control pacing by delivering an electronic pulse.  Pacemakers control only the right side of 
the heart (Minneapolis Heart Institute 2004).    
    Biventricular devices (BIV) are used to treat heart failure by resynchronization of the 
pumping action of the left ventricle, thereby pacing both sides of the heart simultaneously.  
This type of pacing is called cardiac resynchronization therapy (Heart Center Online 2004).  
Biventricular devices have the advantage of being quite effective treatments for patients with 
certain health conditions such as congestive heart failure, but also have the disadvantage of 
being difficult, technically-challenging procedures involving lengthy fluoroscopy times.  The 
ability to timely and successfully place the leads of a biventricular device is user-dependent, 
suggesting that fluoroscopy times will vary significantly depending upon the experience and 
skill of the physicians involved, and that institutions should see a decrease in procedure time 
as these skills improve (Romeyer-Bouchard 2005).
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LITERATURE REVIEW 
 
    A literature review was conducted to identify information on fluoroscopy times and 
associated skin doses for common EP procedures.  One previous study found the mean 
duration of fluoroscopy time (+SD) for the ablation of an accessory pathway, the 
atrioventriclar junction, or atrioventricular nodal re-entrant tachycardia to be 53 +50 minutes 
(median 37; range 1-448 minutes) (Rosenthal 1998).  The duration of time for adult ablations 
was 58+55 minutes (median 45).  There was no significant difference in duration of 
fluoroscopy time between the different ablation procedures.  This study also identified sex, 
and success or failure of the procedure as independent predictors of fluoroscopy duration.  
Men required longer times than women, and those patients undergoing a failed ablation 
procedure had times that exceeded those with a successful procedure by 50%.  The mean 
dose to the skin was estimated to be 130 + 130 rad (median 90; range 3-1110 rad), and 
showed that dose likely to cause injury to the skin (200 rad) was exceeded in 22% of adult 
procedures performed.  One percent of the procedures were associated with a dose of greater 
than 700 rad, which is likely to cause permanent destruction of the skins epithelium 
(Rosenthal 1998)(Wagner 1996). 
    Another study by Park et al have reported mean fluoroscopy times of 47+31 minutes (Park 
1996) while Lindsay et al report 50+31 minutes (Lindsay 1992) for ablation procedures. 
    One study by Manolis at al (2001) found significant differences in fluoroscopy time 
duration between ablation procedures of accessory pathways, slow AV node pathways, atrial 
and ventricular tachycardias, atrial flutter, and AV node/His bundle.  Procedures involving 
the ablation for atrial flutter, multiple accessory pathways and certain atrial and ventricular 
tachycardia required the longest mean times (68+37, 89+54, 46+35, 45+28 minutes 
respectively), while ablation of the slow AV nodal pathway and AV node/His bundle 
required the least amount of fluoroscopy time (27+24, 14+8 minutes respectively).  The 
overall mean fluoroscopy time was 43+40 minutes (Manolis 2001). 
    Another study reports mean fluoroscopy times of 57+30 minutes for paroxysmal atrial 
fibrillation (PAF), 20+10 minutes for atrial flutter, and 22+21 minutes for accessory pathway 
ablation (Macle 2003).   
    One study shows a positive correlation (r2 = 0.41) between peak skin dose and total 
fluoroscopy time for different ablation procedures.  This same study also shows a positive 
correlation (r2 = 0.34) between increases in body mass index and the ratio of peak skin dose 
to fluoroscopy time.  Although neither of these variables is of predictive value for individual 
cases, longer fluoroscopy times and increases in patient size do lead to higher radiation doses 
to the skin.  The mean BMI reported for this study was 28+5. (Paisey 2004).   
    Chida et al demonstrated a better correlation between the peak skin dose and fluoroscopy 
time for ablation procedures with an r2-value of 0.64.  They also looked at the correlation 
between dose and the weight-fluoroscopy time product for non-ablation cardiac interventions 
and reported r2-values of 0.50 (Chida 2006).  
    Iida et al have shown that entrance skin dose correlates well with the product of BMI and 
fluoroscopy time for general diagnostic (angiography) and interventional (transcatheter 
arterial embolization) radiology procedures, and obtained r2-values of 0.91 and 0.78, 
respectively.  BMI and fluoroscopy time products were less than approximately 500 and 
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1,000 for diagnostic and interventional procedures, respectively.  Consistent with other 
reported studies, a poor correlation was seen between dose and total fluoroscopy time (Iida 
2004). 
    Several articles reported the total fluoroscopy times for biventricular devices.  Kostas 
(2005) reported fluoroscopy times of 35+22 minutes, and Romeyer-Bouchard (2005) 
reported lower times of 23+19 minutes when utilizing a simplified technique for the 
implantation of such devices. 
    Another study (AAMP 2002) looked not only at the fluoroscopy times for BIV systems, 
but also measured the entrance skin dose using ISP Radiochromic Film XR-R, like that used 
in this project.  They reported fluoroscopy times of 30-200 minutes with a median of 90 
minutes, and skin doses of 80-600 rad with a median of 250 rad.  A summary of the literature 
reviewed is given below in Table 2: 
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Table 2:  Summary of literature reviewed for adult ablation and 
biventricular device (BIV) procedures. 
 
Author 
Study 
Size Procedure Diagnosis 
Fluoroscopy 
Time (minutes) 
Skin Dose 
(rad) 
Manolis 132 Ablation 
Multiple Accessory 
Pathways Mean of 89+54 Not Reported 
Manolis 15 Ablation Atrial Flutter Mean of 68+37 Not Reported 
Rosenthal 799 Ablation Not Specified Mean of 58+55 130 (estimate) 
Macle 
 
43 
 
Ablation 
Paroxysmal Atrial 
Fibrillation Mean of 57+30 
 
Not Reported 
Lindsay 
 
108 
 
Ablation 
Supraventricular 
Tachycardia Mean of 50+31 
 
Not Reported 
Park 
 
500 
 
Ablation Not Specified Mean of 47+31 
93+/-62 
(estimate) 
Manolis 24 Ablation Atrial Tachycardia Mean of 46+35 Not Reported 
Manolis 
 
29 
 
Ablation 
Ventricular 
Tachycardia Mean of 45+28 
 
Not Reported 
Manolis 119 Ablation AV Nodal Pathway Mean of 27+24 Not Reported 
Macle 16 Ablation Accessory Pathway Mean of 22+21 Not Reported 
Macle 20 Ablation Atrial Flutter Mean of 20+10  Not Reported 
Manolis 
 
7 
 
Ablation 
AV Node/His 
Bundle Mean of 14+8 
 
Not Reported 
Paisey 
 
28 
 
Ablation Not Specified 
3.1-53.6 
Median of 14.3 
2-62 
Median of 12 
Paisey 
 
10 
 
Biventricular Not Specified 
4.9-40.1 
Median of 21.5 
5-93 
Median of 23 
Kostas 14 Biventricular Not Specified Mean of 35+22 Not Reported 
Romeyer-
Bouchard 103 Biventricular
 
Not Specified Mean of 23+19 
 
Not Reported 
AAPM 13 Biventricular
 
Not Specified 
30-200 
Median of 90 
80-600 
Median of 250 
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PROJECT APPROVAL PROCESS 
 
Office of Human Research Ethics Institutional Review Board (IRB) Process 
    Research conducted for this project was subject to review and approval by the UNC 
School of Medicine Institutional Review Board (IRB).  IRB committees at UNC are 
administered through the Office of Human Research Ethics and serve the primary purpose of 
protecting the rights and welfare of human subjects.  The three levels of IRB review are full 
board review, expedited review, and review to determine if a project is exempt from 
continuing review (Office of Human Research Ethics 2006). 
    IRB approval was gained in two phases.  Phase 1 was titled “Identification of Likely High 
Radiation Dose Procedures through the Evaluation of Fluoroscopic Times in an 
Electrophysiology Lab” and required submitting the completed “Application for Research 
Requesting and IRB Waiver of Consent and HIPAA Authorization” (Appendix B).  This 
specific application is used when research involves only a review of existing patient records.  
HIPAA stands for the “Health Insurance Portability and Accountability Act” of 1996 and 
focuses on protecting the privacy and security of an individual’s protected health information 
(PHI).  PHI consists of individual data that may potentially identify a patient or human 
subject, such as name or account numbers.  Since the first phase of research involved access 
to PHI, such as patient names, a waiver from the requirement to obtain HIPAA authorization 
by those patients for which fluoroscopy times were evaluated was necessary.  Because strict 
confidential measures were utilized to protect this information, and because the research 
would not be practical without such a waiver or without access to the potential identifiers, the 
waiver was granted (Office of Human Research Ethics 2006).  Phase 1 research was deemed 
exempt from continuing IRB review, and the approval letter is found in Appendix C.   
    Phase 2 was titled “The Use of a Radiochromic Film for the Evaluation of Skin Dose 
During Extended Fluoroscopy Procedures in an Electrophysiology Lab” and required 
completing and submitting the full “Application for IRB Approval of Human Subjects 
Research” (Appendix B).  The application received expedited review and the research was 
approved for one year on June 10, 2005 under the assigned IRB study number of 05-RAD-
358 (Appendix B).  Subject written consent for participation in phase 2 was not necessary, 
however subjects were supplied with a “Subject Information Sheet” describing the nature of 
the research they were participating in, as required by the IRB (Appendix C). 
 
Required Training 
    Effective March 15, 2005, all faculty, staff and students involved in research using human 
subjects at UNC are required to complete a web-based training program on issues related to 
human subject research.  All IRB applications submitted are required to include evidence that 
all study personnel have successfully completed with a passing score of 75% the appropriate 
Collaborative IRB Training Initiative (CITI) modules (Office of Human Research Ethics 
2006).  Evidence of completing the required biomedical research module is located in 
Appendix D. 
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REVIEW OF ELECTROPHYSIOLOGY FLUOROSCOPY LOG 
 
Method of Evaluation 
    A retrospective review of the electrophysiology log containing date of procedure, type of 
procedure performed, physician performing the procedure and total fluoroscopy time was 
conducted. Mean fluoroscopy times for the different categories of electrophysiology 
procedures were determined, as well as mean fluoroscopy times for each physician 
performing the procedures.  This information was used to identify likely high-dose EP 
procedures.  High-dose procedures are those with times likely to produce doses approaching 
the threshold for causing injury to the patient. 
 
Results 
    Of the 261 documented procedures for the time period between March 27, 2003 and 
March 30, 2005, the fluoroscopy times for 247 procedures were analyzed.  There were 
approximately 11 months during this time period for which no information on fluoroscopy 
time was available.  Fluoroscopy time was not properly documented for 11 of the 261 
procedures, and the fluoroscopy time for three pediatric cases (66, 28, and 12 minutes) were 
not used in this study.  The physician performing the procedure was not recorded for 22 of 
the 247 records reviewed.  The procedures that were reviewed, including date, physician 
code, fluoroscopy time, and type of procedure are located in Appendix E. 
    The 247 procedures evaluated were categorized into six groups of electrophysiology 
procedures performed at UNC and include:  radiofrequency catheter ablation (ABL), 
biventricular device (BIV), internal cardioverter defibrillator (ICD), electrophysiology study 
(EPS), pacemaker (PM), and change out (CO).  
    Mean fluoroscopy times (+SD), with the median and range values in parenthesis, were 
determined to be 62+48 minutes (44, 1-191 minutes) for ABL, 51+28 minutes (46, 13-121 
minutes) for BIV, 14+13 minutes (10, 1-61 minutes) for ICD, 13+14 minutes (10, 2-58 
minutes) for EPS, 13+10 minutes (10, 2-53 minutes) for PM, and 4+7 minutes (1, 1-39 
minutes) for CO.  A graphical representation of the mean fluoroscopy time for EP procedures 
is shown in Figure 3.  Procedures with fluoroscopy times greater than 60 minutes are shown 
in Table 3. 
    Figure 3:  Mean fluoroscopy time in minutes for the 6 categories 
of EP procedures evaluated. 
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    Procedures were also evaluated by physician performing the procedure.  Figure 4 shows 
the average fluoroscopy time for the six categories of procedures for the two primary 
physicians performing 212 of the 225 adequately documented procedures included in this 
study. 
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Table 3: Procedures with fluoroscopy times greater than 60 minutes. 
 
Type of 
Procedure 
Total 
Procedures 
# Procedures 
>60 min. (%) 
# Procedures 
>90 min. (%) 
# Procedures 
>120 min. (%) 
ABL 33 12 (36) 8 (24) 5 (15) 
BIV 28 7 (25) 2 (7) 2 (7) 
EPS 13 1 (2) 0 (0) 0 (0) 
PM 71 0 (0) 0 (0) 0 (0) 
CO 46 0 (0) 0 (0) 0 (0) 
 
Figure 4:  Mean fluoroscopy time by physician. 
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Discussion 
    The data in this study as well as and others in the literature show clearly the great 
variability in the amount of fluoroscopy time used for a given procedure, as there is great 
variability in the way a procedure is performed.  Conversations with EP staff point out the 
variability in patient anatomy and pathology which contributes to the wide variability in 
fluoroscopy times.  For example, some ablation procedures require the placement of only one 
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catheter in the heart, while other types may require up to five and thus necessitate longer 
fluoroscopy times.  
    Consistent with the findings of Romeyer-Bouchard (2005), a decrease in the overall mean 
fluoroscopy time for BIV procedures during the observed time period was observed.  
However, there has been little change in the overall mean time of ablation procedures.   
    Based on the retrospective review of the procedures recorded in the EP fluoroscopy log, 
radiofrequency catheter ablations and biventricular device implants are the two procedures 
likely to have fluoroscopy times long enough to deliver a dose in excess of the threshold for 
radiation-induced injury.  These two procedures were selected to conduct measurements of 
patient skin dose, and the results of this research are detailed below. 
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DOSE MONITORING FOR ABLATION AND BIVENTRICULAR PROCEDURES 
 
Measuring Radiation Dose 
    The likelihood of injury, such as deterministic effects to a patient, can be predicted by the 
dose to the skin.  Many methods exist for either the indirect estimation or direct measurement 
of skin dose.  
    Indirect methods for the estimation of radiation doses often require detailed recording, and 
thus prove to be time consuming and impractical for routine application.  It requires that 
information on equipment operating parameters (kVp, mA, pulse rate, pulse width, etc), 
location of the patient with respect to the x-ray source, source-to-image intensifier distances 
(SID), and other variables be known.  One must also know the measured beam intensity for 
the different operating techniques and any appropriate backscatter factors in order to 
accurately estimate skin dose.  The dynamic nature of the many variables involved in a single 
procedure compound the complexity and difficulty of indirect estimation of skin dose.   
    Methods exist for the direct measurement of radiation doses and include the use of 
thermoluminescent dosimeters (TLDs), diodes or metal-oxide semiconductor field-effect 
transistor (MOSFET) detectors, and photographic and radiochromic films (Mahesh 2001).  In 
practice, many of these devices are often expensive, require special calibrations, prove 
difficult or tedious to place on the patient, require a level of expertise for operation, or may 
even interfere with the procedure by obscuring the region of diagnostic or clinical interest.  
    Although time and resource consuming, the direct measurement of radiation dose is the 
only way to determine the actual skin dose received by patients undergoing high-dose 
fluoroscopy procedures, and may be the best way to evaluate the level of risk for such 
patients.   
 
Radiochromic Film 
    The direct measurement of peak skin dose was achieved using a radiochromic dosimetry 
film that is specifically designed to measure skin dose during fluoroscopically-guided 
procedures.  The film is easy to use, is large enough to intercept the entire x-ray beam, and 
most importantly does not interfere with the clinical procedure in any way.   
    The main component of the film is diacetylene, and the underlying mechanism is solid-
state polymerization (ISP 2004).  The unexposed film is orange in color, turning to a green-
black color following exposure to ionizing radiation.    
    This type of film was developed specifically to measure low-energy photons (<200 keV) 
and has a range of energy independence from 60-120 keV (the diagnostic energy range used 
in EP).  The dynamic range of the film is 10 rad to 1500 rad, and it is supplied in 14”x17” 
sheets.  The film is self-developing, requires no chemicals, is unaffected by water, blood and 
other aqueous fluids, is dose rate and dose fractionation independent, and is not light 
sensitive (ISP 2004).   
    The film is also relatively inexpensive; costing $20 per 14” x 17” sheet at the time of 
purchase in June 2005.  The University of North Carolina at Chapel Hill Department of 
Environment, Health and Safety funded the purchase of film used for this research. 
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    For this study, the dose to the film was determined by scanning the exposed film for each 
subject with a flatbed scanner and using a previously determined calibration curve of known 
doses and pixel values.   
    The fluoroscopic x-ray unit used for calibration of the radiochromic film was the Toshiba 
Model XTP—8100G.  A RadCal MDH  Model 1515 electronic dosimeter with a 6 cm3 
ionization chamber was used to measure the in-air exposure rates used to generate a dose-
response curve for the radiochromic film.  The MDH was calibrated by the manufacturer to a 
NIST-traceable source with an accuracy of +/- 4%. 
 
Calibration Tablet 
    A calibration curve was generated and used to determine the corresponding dose from 
measured pixel values obtained during film scanning.  Necessary equipment included 
GAFCHROMIC XR Type R dosimetry film, fluoroscopic x-ray unit, calibrated ion chamber 
with electrometer, color flat-bed scanner, and a computer with Photoshop software.   
    The calibration procedure was performed using the methods described below: 
1. The lot number of the dosimetry film was noted.  Although only one lot number of film 
was used for this study, a separate calibration curve would have been required for each 
lot number. 
2. The x-ray equipment was placed in the orientation in which it is used clinically with the 
x-ray beam pointing up.   
3. The ion chamber was placed in the center of the exposure field, resting on the exit 
window of the tube housing and connected to the electrometer.  The image of the ion 
chamber was observed on the monitor to ensure that proper centering and that no part of 
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the chamber was outside of the radiation field.  It was repositioned as necessary.  The 
configuration of the ion chamber and x-ray tube housing is shown below in Figure 5. 
 
Figure 5:  Ion chamber configuration with respect to the x-ray tube housing. 
 
           
 
4. Manual operating techniques of 90 kVp (+/- 1.4%), 100 mA, 10.2 ms pulse width, and 15 
pulses/second were used during the calibration process. 
5. The exposure rate (R minute-1) was determined 5 times by integrating the total exposure 
to the ion chamber for a period of 1 minute over different heating stages of the x-ray tube 
in order to account for any variation.  A mean exposure rate of 47.2 R minute-1 was 
obtained, with maximum and minimum values of 47.3 and 47.0 R minute-1 respectively.  
The percent heat load ranged from 5-50% during calibration. 
6. Using the measured exposure rate, the exposure times necessary to give total doses of 
approximately 50R, 100R, 200R, 300R, 400R, 500R, 600R, 700R, 800R, 900, and 1000R 
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were determined.  It was not necessary to hit a dose precisely, but only to be close.  The 
actual dose to the film is the product of the exposure rate and total exposure time to the 
piece of film.  To reduce the time it took to expose the films, stacks of up to three films 
were exposed simultaneously.  After the first dose of D1 was given to a stack, one film 
was removed and the remaining two films were given a second dose D2.  The second film 
was then removed and a third dose D3 was given to the remaining film.  The total dose 
given to the three films are D1, D1+D2, and D1+D2+D3.   
7. A sheet of radiochromic film was cut into 12 2”x2” pieces to make up the calibration 
tablet.  The pieces were numbered 1-12 for identification, with tablet number 1 serving as 
the unexposed reference film. 
8. The stacks of film were placed in the same plane as the center of the ion chamber during 
the exposure rate measurements.  A supporting device was used to raise the film to the 
proper plane, and the films rested on a thin piece of cellophane mounted to a piece of 
cardstock with a hole in the center.  The set-up of the film support device and the device 
with 2”x2” pieces of film in place is shown below in Figures 6. 
9. The remaining calibration tablets were exposed as described in step 6.  The date and time 
of exposure was recorded.  The calibration films were kept stored in the dark, unless they 
were removed for scanning.  The date of exposure, minutes exposed, and total exposure 
is shown below for each tablet in Table 4. 
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Figure 6:  Set-up of the radiochromic film and supporting 
device with respect to the x-ray tube. 
 
           
Radiochromic Film Film Supporting Device      
 
Table 4: Calibration information for tablet #1. 
 
Film Number Date of Exposure Minutes Exposed Total Dose (rad) 
1 N/A 0.0 0.0 
2 09/02/2005 1.1 51.0 
3 09/02/2005 2.2 102.0 
4 09/02/2005 4.3 199.3 
5 09/02/2005 6.5 301.3 
6 09/02/2005 8.7 403.2 
7 09/02/2005 10.7 495.9 
8 09/02/2005 12.9 597.9 
9 09/02/2005 15.0 695.3 
10 08/25/2005 17.8 825.0 
11 08/25/2005 20.0 927.0 
12 08/25/2005 22.5 1042.9 
 
For confirmation and comparison purposes, a second calibration tablet was created using 
similar methods and techniques described above.  A mean exposure rate of 32.2 R 
minute-1 was observed during this calibration which used 90 kVp, 100 mA, 7 ms pulse 
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width, and 15 pulses/second.  Information for the second calibration set is given below in 
Table 5. 
Table 5: Calibration information for tablet #2. 
 
Film Number Date of Exposure Minutes Exposed Total Dose (R) 
1 N/A 0.0 0.0 
2 02/13/2006 6.0 193.4 
3 02/13/2006 12.0 386.8 
4 02/13/2006 18.0 580.2 
5 02/13/2006 24.0 773.6 
6 02/13/2006 30.0 967.0 
7 02/13/2006 38.0 1224.9 
 
10. Post-irradiation scans of the calibration tablets were performed on an Epson model 1680 
flat-bed scanner.   The glass bed of the scanner was wiped with a Kim-Wipe tissue prior 
to each use to remove any dust or debris.  Four calibration tablets were scanned at a time 
by placing them in the center of an opaque white plastic sheet with a 4” x 4” cutout in the 
center.  This device served to provide consistent centering and border color during 
scanning.  Pertinent scanner information and utilized settings are provided below in Table 
6.   
Table 6: Epson Model 1680 flatbed scanner settings. 
 
Serial Numbers  39001, 37511 
Preview Yes 
Document Type Reflective 
Auto Exposure Type Photo 
Image Type 24-Bit 
Scan Quality Best 
Resolution 300 DPI 
Target Size 8.5" x 11.7" 
 
11. Film response is defined as the ratio of the color intensity (red, green, or blue) of the non-
exposed film to the diminishing same color intensity of the exposed film.  The red 
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component of the scanned image was used in this ratio as it has been shown to have the 
highest sensitivity, with the blue component shown to be the least sensitive (Thomas 
2003). 
12. The tablets were scanned into Photoshop software to determine the mean red channel 
pixel values.  These values were obtained for the 0.5” x 0.5” area in the center of each 
tablet, which corresponds to 22,500 pixels.  This area of each tablet was selected and 
evaluated because it corresponds to the approximate size of the ion chamber and also to 
the approximate location in the x-ray field where the ion chamber was placed for the 
initial exposure-rate measurements.  The images of the scanned first calibration tablet are 
shown below in Figure 7, with numbers 1-4 on the left, 5-8 in the middle, and 9-12 on the 
right.  To evaluate the effects of tablet placement, tablets 1 and 2 were scanned together 
with tablets 11 and 12, which resulted in pixel value percentage changes of 0.2-0.6%.    
Figure 7:  Scanned images of calibration tablet #1 (numbers 1-4, 5-8, 9-12). 
 
     
 
 
13. Dini et al. (2003) have shown that post-exposure response of the film increases 
approximately 16% within the first 24 hours of exposure and increases approximately 4% 
over the next 24 hours.  They observed only a growth of approximately 2% for the 
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following 300 hours (12.5 days).  For this project, final pixel values were determined 
during this stable post-irradiation period of 13 and 14 days for calibration tablets one and 
two respectively.  Since it was thought that waiting two weeks to accurately determine a 
subject’s skin dose may be too long, especially in the event of an exceedingly high dose, 
calibration tablet two was also scanned at 1, 3, and 7 days post irradiation; thus allowing 
determination of a subject’s dose in a shorter period of time.   
14. To ensure consistent operation and performance of the scanner over the time span of this 
project, a test pattern was created and scanned prior to all other film scans.  The pattern 
was generated using a printing process called dye sublimation, which uses heated printer 
heads to vaporize solid dyes of yellow, magenta, cyan, and black in color from their 
plastic sheets into the surface of glossy paper before cooling and returning to a solid 
form.  The result is photo-lab-quality images with images that are not made up as 
individual dots and have a very uniform appearing color for scanning.  Since the dyes 
actually penetrate the paper, the images are less vulnerable to fading and distortion than 
with other methods of printing (How Stuff Works 2005).   
For the test pattern, the mean red channel pixel values were determined and evaluated for 
consistency in the eight areas identified in the test pattern image below.  Values obtained 
during the scanning of the daily test pattern is located in Appendix F. 
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Figure 8:  Scanned image of test pattern showing the eight different areas evaluated. 
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15. The sixteen data points for the 13 and 14-day post-irradiation scans of the two calibration 
tablets were combined to create one calibration curve for scanner station 1.  The ratio of 
the red channel values for the non-irradiated reference tablet to the irradiated tablet 
(Cni/Ci) was plotted against the measured dose (rad).  Using the fourteen measurements of 
the non-irradiated reference tablet that were taken from 9/6/2005-2/27/2006, an overall 
mean Cni value of 229.71 was obtained.  This value was used for the “final” calibration 
curve which was graphed using Microsoft Excel and is shown below in Figure 9.   
Figure 9:  Final calibration curve for scanner station 1. 
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16. A 14-day post-irradiation calibration curve was also determined using scanner station 4 
and values for the second calibration tablet.  This curve was useful because it served as a 
backup when scanner station 1 suffered failure towards the end of this project.  The 
equation of the linear regression straight line for the 14-day post-irradiation scan on 
station 4 was determined to be y = 0.0064x + 1.  The detailed values used to generate the 
calibration curves for scanners 1 and 4 are located in Appendices G and H.  
17. To avoid any non-linear aspect of the curve and because such high doses were not 
encountered during this project, calibration curves used to determine subject doses did 
not include the highest measured dose of 1224.9 rad from the second calibration tablet.  
 
Dose Measurement Protocols 
    Working closely with the Cardiology administrative staff handling the scheduling of all 
electrophysiology procedures, scheduling information for ablation and biventricular 
procedures was obtained.  Patient dose monitoring began on September 9, 2005 and 
continued until June 8, 2006. 
    Prior to the start of each procedure, the research project was described to each subject.  
They were provided the required Subject Information Sheet, oral approval was obtained and 
their height and weight values were recorded.     
    For each subject, a single piece of 14” x 17” film was placed underneath the thin bed sheet 
on which the subject lies during the procedure.  The film rested between the subjects’ back 
and the supporting table top.  The top edge of the film was placed at approximately the upper 
part of the shoulder where it meets the neck, and was centered roughly to the area of the 
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heart.   To prevent contamination of the film with blood or other potentially hazardous 
materials, each film was place inside of a thin protective plastic cover prior to use.     
    Variables recorded for each procedure include demographic details of the patient such as 
age, sex, height and weight, procedure category (i.e. ABL), nature of diagnosis (i.e. atrial 
flutter), physician(s), and fluoroscopy time.  Equipment variables such as continuous vs. 
specific pulse rate, phosphor size used, and table height information were recorded as 
available and whenever possible.  A procedure information sheet was developed and used to 
record this information for each subject and is located in Appendix I. 
 
Subject Film Scanning Protocols 
    The absorbed dose for each subject was determined by first visually identifying the darkest 
exposed area of the film, which was centered in the same 4”x4” opening in the white plastic 
device that was used for scanning the calibration tables.  Scanning was performed using the 
protocols described in steps 10-14 of “Calibration Tablet” in this section.  Ten attempts were 
then made to identify the area of the scanned image having the lowest mean red pixel value 
which represents the area receiving the highest absorbed dose.   
    Peak skin dose was determined by substituting the lowest mean red pixel value into the 
appropriate linearly regressed straight line equation (y=βx+α, where α is the intercept and β 
is the slope) as determined in steps 15 and 16 of the calibration tablet procedure.   
 
Results 
    The purpose of the daily test pattern was to identify any irregularity in scanner operation.  
The daily pattern was comprised of colors having red channel pixel values ranging from 
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approximately 25-210, which correspond to doses of approximately 15 to 1310 rad.  Scanner 
performance was very good over the range of pixel values evaluated, as demonstrated by the 
coefficients of variation which ranged from only 0.4% to 2.1%.  This is consistent with other 
reported coefficients of variation for flatbed scanners of 1.8% (Thomas 2005).  The red 
channel pixel values obtained for the daily test pattern are provided in Appendix F. 
    For the thirty-three subjects, thirty procedures resulted in accurate fluoroscopic time and 
measurable dose.  One procedure was performed with the x-ray tube positioned over the 
patient so that exit dose was recorded rather than entrance dose; however no visible 
darkening was noted on this subject’s film.  An artifact was seen on the video monitor during 
another case and the film was removed by the physician thinking the artifact might have been 
caused by the film.  The artifact was actually caused by the improper placement of a cardiac 
mapping system often used during ablation procedures.  The third procedure that was omitted 
was due to the loss of fluoroscopy time because of a procedural error involving the time 
recording device.   
    Final red channel values were obtained between 13 and 17 days post-irradiation for the 
thirty measured skin doses.  As an example, the scanned film for subjects 2 and 27 are shown 
below in Figure 10.  Note the stationary position of the x-ray tube during the ablation 
procedure on the left (subject 2) as compared to the more dynamic irradiation pattern of the 
BIV procedure for subject 27 (on the right).    
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Figure 10:  Scanned films of subjects 2 and 27. 
 
                    
 
 
    Scanned images for subject 23 are shown below in Figure 11.  The image on the right is 
with the centering template in place and is the image used for final pixel value determination. 
Figure 11:  Scanned image for subject 23 with and without centering template. 
 
                   
    The mean, standard deviation, maximum, and minimum values for patient weight, BMI, 
fluoroscopy time, and peak skin dose are given below in Table 7.  This table also reports this 
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information by type of procedure as well as by physician performing the procedure.  The 
number of procedures is given as well. 
Table 7:  Summary of descriptive statistics for patient weight, BMI, fluoroscopy time, and 
peak skin dose by type of procedure and physician. 
 
All Procedures Mean 
Standard 
Deviation Maximum Minimum 
Weight (lbs) 204.0 57.7 331.0 116.0 
Body Mass Index (BMI) 30.0 7.0 43.7 19.3 
Fluoroscopy time (min) 46.2 24.5 94.0 12.5 
Peak skin dose (rad) 149.9 142.1 764.4 31.8 
Number of Procedures 30       
Ablation Only Mean 
Standard 
Deviation Maximum Minimum 
Weight (lbs) 181.4 40.2 240.0 116.0 
Body Mass Index (BMI) 27.4 5.3 37.8 19.3 
Fluoroscopy time (min) 57.4 27.8 94.0 12.5 
Peak skin dose (rad) 133.2 94.0 366.9 31.8 
Number of Procedures 14       
BIV Only Mean 
Standard 
Deviation Maximum Minimum 
Weight (lbs) 223.8 64.4 331.0 146.0 
Body Mass Index (BMI) 32.4 7.6 43.7 21.1 
Fluoroscopy time (min) 36.4 16.5 71.4 19.3 
Peak skin dose (rad) 164.5 175.8 764.4 38.6 
Number of Procedures 16       
Physician A Mean 
Standard 
Deviation Maximum Minimum 
Weight (lbs) 213.1 56.1 331.0 146.0 
Body Mass Index (BMI) 30.9 6.9 43.2 21.1 
Fluoroscopy time (min) 44.3 25.4 94.0 19.3 
Peak skin dose (rad) 144.1 94.6 366.9 38.6 
Number of Procedures 18       
Physician B Mean 
Standard 
Deviation Maximum Minimum 
Weight (lbs) 190.4 59.9 331.0 116.0 
Body Mass Index (BMI) 28.8 7.2 43.7 19.3 
Fluoroscopy time (min) 49.0 23.9 85.1 12.5 
Peak skin dose (rad) 158.6 198.2 764.4 31.8 
Number of Procedures 12       
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    Fifty percent of ablation procedures exceeded 1 hour of fluoroscopy while fourteen percent 
exceed 90 minutes.  Only twelve percent of the BIV cases exceed 60 minutes of fluoroscopy.  
A summary of the procedures with fluoroscopy times greater than 1 hour is provided below 
in Table 8.   
Table 8:  Subjects monitored with fluoroscopy times greater than 60 minutes. 
Type of 
Procedure 
Total 
Procedures 
Procedures >60 
minutes (%) 
Procedures >90 
minutes (%) 
Procedures >120 
minutes (%) 
ABL 14 7 (50) 2 (14) 0 (0) 
BIV 16 2 (12) 0 (0) 0 (0) 
 
    Forty percent of the subjects had a BMI corresponding to a CDC weight classification of 
obese.  Descriptive statistics of the peak skin dose by weight classification are given below in 
Table 9. 
Table 9:  Descriptive statistics of the peak skin dose by BMI weight classification. 
 
  
Normal 
BMI of 18.5-24.9 
Overweight 
BMI of 25-29.9 
Obese 
BMI of 30 and greater
Number of Subjects 9 9 12 
% of Total Subjects 30% 30% 40% 
    
Mean Dose (rad) 72.4 119.1 231.1 
Standard Deviation 30.3 75.4 188.6 
Minimum 31.8 38.6 71.6 
Maximum 111.0 264.7 764.4 
Subjects (%) in BMI 
Class > 200 rad 0 (0) 2 (25) 5 (38) 
    
Mean Dose Rate 
(rad minute-1) 1.9 2.5 5.3 
Standard Deviation 0.6 0.9 3.6 
Minimum 1.0 1.2 2.5 
Maximum 2.8 3.8 15.7 
 
    Overall, male subjects (n=20) weighed more and had a higher BMI than female subjects 
(n=10).  Although fluoroscopy time differed very little between the sexes, male subjects 
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received mean peak skin doses double that of female subjects.  No female subjects exceeded 
a skin dose of 200 rad.  Detailed information related to subject sex is provided below in 
Table 10. 
Table 10:  Subject weight, BMI, fluoroscopy time, and peak skin dose by sex. 
 
Weight (lbs) Mean 
Standard 
Deviation Maximum Minimum 
Male 223.5 54.5 331.0 147.0 
Female 165.1 44.2 240.0 116.0 
BMI     
Male 31.1 6.9 43.7 21.1 
Female 27.8 7.0 39.9 19.3 
Fluoroscopy Time (min)     
Male 45.2 24.4 91.7 12.5 
Female 48.3 26.0 95.0 25.8 
Peak Skin Dose (rad)     
Male 179.8 166.0 764.4 31.8 
Female 90.2 31.1 155.8 37.2 
 
    The overall mean entrance skin dose rate for this project was determined to be 3.4 rad 
minute-1 for both ablation and BIV procedures.  This is consistent with the typical 
fluoroscopy ESE level of 2.5 R minute-1 as noted by the IAEA (1996) when assuming typical 
backscatter factors of approximately 20-40% (Wall 1996).  As one would expect, the mean 
dose rate increases with higher subject BMI, and these values are provided above in Table 9 
for the different BMI classifications.  A complete listing of subject information, procedural 
specifics, and film scanning/dose information that was collected for the thirty study 
participants is provided in Appendix J.      
    Scatter plots and statistical parameters were generated using Microsoft Excel.  The 
correlation between different grouped parameters has been described by the r2-value (the 
square of the correlation coefficient).  This value describes the linear least squares fit 
relationship between the data sets.   
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    Peak skin dose was correlated to patient weight, weight x fluoroscopy time, BMI, BMI x 
fluoroscopy time, and fluoroscopy time with r2-values for all procedures combined of 0.37, 
0.41, 0.30, 0.36, and 0.12 respectively.  An increasing r2-value means a stronger relationship 
between the variables compared.  Another way of thinking of this for this project is how 
much of the variability in peak skin dose is due to variability in weight, BMI and fluoroscopy 
time.  See Figures 12-16.  The straight line on each figure below represents a linear 
regression analysis.   
Figure 12:  Scatter plot of peak skin dose in rad vs. subject weight in pounds. 
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Figure 13:  Scatter plot of peak skin dose in rad vs. subject weight x fluoroscopy time. 
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 Figure 14:  Scatter plot of peak skin dose in rad vs. subject BMI. 
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Figure 15:  Scatter plot of peak skin dose in rad vs. subject BMI x fluoroscopy time. 
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Figure 16:  Scatter plot of peak skin dose in rad vs. fluoroscopy time. 
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     The correlation between these parameters was determined for individual procedure types, 
as well as with and without the outlying data point one.  A summary of the calculated r2-
values is presented below in Table 11.   
Table 11:  Summary of r2-values for the correlation of peak skin dose to patient weight, 
weight x fluoroscopy time, BMI, BMI x fluoroscopy time, and fluoroscopy time. 
 
 
D
ose vs. W
eight 
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D
ose vs. T
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e 
Ablation Only 0.23 0.68 0.13 0.61 0.37 
BIV Only 0.43 0.44 0.37 0.44 0.18 
BIV   (No Subject 1) 0.45 0.60 0.42 0.65 0.37 
All Procedures 0.37 0.41 0.30 0.36 0.12 
All Procedures (No Subject 1) 0.26 0.63 0.21 0.59 0.32 
 
Discussion 
    During this project, we were able to develop accurate and reproducible procedures for the 
calibration of radiochromic film to be used for the monitoring of the peak skin dose for 
subjects undergoing extended fluoroscopy procedures in an EP Lab.  The data show a 
positive correlation between the variables which we compared; however the linear 
correlation is generally poor.  The mean fluoroscopy time (57.4 minutes) and dose (133.2 
rad) for ablation procedures were found to be consistent with values of 58 minutes and 130 
rad reported by Rosenthal (1998); however peak skin dose does not correlate as well with the 
product of BMI and fluoroscopy time as reported by Iida (2004).  Our data show an overall 
r2-value of 0.36 while Iida demonstrated better correlation with r2-values of 0.91 for 
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 diagnostic and 0.78 for interventional radiology procedures that involved 19 and 26 subjects 
respectively.   
    Our r2-value of 0.41 for the overall correlation between the product of subject weight and 
fluoroscopy time is lower than the r2-value of 0.50 reported by Chida (2006); however our r2-
value of 0.68 for the correlation among ablation procedures is much higher.   
    Overall, fluoroscopy time alone does not correlate well to dose and is a poor predictor of 
risk to which a subject undergoing ablation or BIV procedures may be exposed.  Our r2-value 
of 0.37 for ablation procedures is lower than the value of 0.64 reported by Chida (2006) for 
the same procedure type.  The subjects in the Chida study were much smaller than our 
subjects and had a mean weight of only approximately 130+20 pounds (Chida 2006).  This 
significant difference in weight between the two study groups may explain the different 
correlation values. 
    Although a significant positive correlation was demonstrated to exist between peak skin 
dose and the product of both patient weight and BMI multiplied by the total fluoroscopy 
time, the variability due to other factors is too large to use any of these as a sole predictor of 
dose and subsequent risk.   
    Subject 1 is an outlier in Figures 12-16 and deserves discussion.  This BIV subject had the 
highest BMI of all study participants (43.7), tied for the highest weight at 331 lbs, and 
received a peak skin dose high enough to cause permanent destruction of the epithelium.  
Although the dose was unusually high for the fluoroscopy time as compared to other 
subjects, it points out the importance of other factors in the dose variability.  Medical 
procedures involving fluoroscopy are dynamic in nature and can vary with each subject 
undergoing the same type of procedure.  Body composition, influenced by age and specific 
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 pathology, or placement of the patient with respect to the x-ray tube, and mode of equipment 
operation may have contributed to the higher peak skin dose for this subject.  Assuming no 
measurement errors, if this subject underwent the lengthiest ablation procedures monitored  
in this study (94 minutes), then their peak skin dose would have approached 1,500 rad; a dose 
which the JCAHO considers to be a sentinel event involving serious injury or the risk thereof 
(JCAHO 2006).         
    Although the number of subjects evaluated during this project was small (30), none of 
those having a normal BMI (18.5-24.9) or weighing < 200 pounds exceeded a threshold for 
radiation-induced effects (200 rad) as described by Wagner and Archer (1996).  In contrast, 
25% of the overweight and 38% of obese subjects exceeded 200 rad peak skin dose.   
    As with all research, we must consider sources of variability and error throughout the 
project.  There is a strong degree of confidence in the calibration and scanning procedures 
developed for this project, and errors were most likely to occur during the collection and 
recording of subject or procedure information.  Weight and height specifics were collected 
indirectly from either the subject or from anesthesia personnel, and erroneous information 
may have been collected or presented, or the misrecording of information may have 
occurred.  Additionally, fluoroscopy time was often collected after the completion of a 
procedure from the logbook rather from the equipment directly, and again mistakes may have 
been made in the transcribing of fluoroscopy time.
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CONCLUSIONS AND FUTURE DIRECTION 
 
    Overweight and obese subjects undergoing ablation and BIV device implant procedures at 
this institution during this study received peak skin doses in excess of the threshold for 
observable radiation-induced effects.  One must consider that although rare, the likelihood of 
a severe radiation-induced injury during such extended fluoroscopy-guided interventional 
procedures exists.  In this study, the correlation between peak skin dose and fluoroscopy time 
was demonstrated to be poor.  Subject peak skin dose correlated best to the product of weight 
and fluoroscopy time and the product of BMI and time.  Although neither is strong enough  
to accurately predict individual doses, the results are strong enough to make useful 
conclusions.   
    We were able to meet five of the six specific project goals.  This project did not produce 
results strong enough to support the development of accurate methods to indicate to a 
physician when peak skin dose may exceed a threshold for observable radiation-induced 
effects.  However, in the absence of more conclusive information, it is worth noting that if 
the product of a subject’s weight and fluoroscopy time is greater than 11,000 minute-pounds, 
then it is likely that the subject received a peak skin dose in excess of 200 rad.   
    Both in hindsight and for the suggestion of future study, the determination of subject 
thickness at heart level may correlate better to skin dose than either weight or BMI and may 
better assist in the development of such procedures.  This study also did not take into 
consideration the possibility that a subject may have undergone additional procedures 
 
 involving fluoroscopy.  Such procedures, both prior to or after our study, are important to 
consider as they would increase a subject’s risk for developing observable radiation-induced 
effects to a level greater than indicated in this study. 
    The monitoring of patient dose during extended fluoroscopy procedures remains a 
complicated and important consideration.  A facility should consider the routine monitoring 
of skin dose, in particular for those overweight and obese patients appearing to be at 
increased risk.   
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 Appendix A 
Simulated ESE Rates Based Upon Subject Thickness 
 
ABS Mode of 
Operation Phantom kVp mA ms 
ESE 
(R min-1) 
Continuous 3.8 cm Al 82 2.5 n/a 1.7 
30 pulses per second 3.8 cm Al 80 32 2.8 1.75 
15 pulses per second 3.8 cm Al 80 38 3.8 1.35 
7 pulses per second 3.8 cm Al 80 33 4.8 0.7 
      
Continuous 3.8 cm Al + 3" lucite 98 3.5 n/a 3.5 
30 pulses per second 3.8 cm Al + 3" lucite 80 90 3.9 6.6 
15 pulses per second 3.8 cm Al + 3" lucite 80 91 5.9 5.17 
7 pulses per second 3.8 cm Al + 3" lucite 80 69 8.2 2.52 
      
Continuous 3.8 cm Al + 6" lucite 120 3.8 n/a 6.1 
30 pulses per second 3.8 cm Al + 6" lucite 99 117 2.7 9.32 
15 pulses per second 3.8 cm Al + 6" lucite 93 123 5.8 9.1 
7 pulses per second 3.8 cm Al + 6" lucite 81 137 13 7.68 
 
Values obtained on 05/05/2004 
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 Appendix B 
IRB Applications and Approvals 
 
APPLICATION FOR RESEARCH REQUESTING AN IRB WAIVER OF CONSENT 
AND HIPAA AUTHORIZATION 
 
Research for which this form is appropriate generally involves only existing patient records 
or specimens.  If there will be any intervention or interaction (e.g. questionnaires, interviews, 
randomization), or any direct contact of any kind with the subjects of this research, STOP 
HERE. Consent/authorization will need to be obtained, and a full IRB application will be 
required.  
 
PROJECT NUMBER (will be assigned by the IRB)  ___________________________ 
 
TITLE OF PROJECT: Identification of Likely High Radiation Dose Procedures through 
the Evaluation of Fluoroscopic Times in an Electrophysiology Lab.   
 
PRINCIPAL INVESTIGATOR:  Bradford Taylor  
UNC-CH DEPARTMENT:  Environment, Health and Safety  
CAMPUS MAILING ADDRESS: CB# 1650  
212 Finley Golf Course Road 
    Chapel Hill, NC 27517 
 
PID NUMBER OF PRINCIPAL INVESTIGATOR:  7029-00680 
 
PHONE:  919-962-5727 FAX:  919-962-0227  PAGER:  919-216-4564  E-MAIL 
ADDRESS:  Bradford_Taylor@unc.edu 
 
NAME OF SPONSOR:  Marija Ivanovic, Ph.D. 
 
 
Proposal for Research Involving:   Patient Specimens (tissues, blood, serum, etc.) 
(Check all that apply)   Medical Records (custodian may also require form, 
e.g. HD-974 if UNC-HCS) 
  Electronic Information from Clinical Database 
(custodian may also require form) 
 
1. Scientific purpose of the study:  Provide a brief summary of the background 
information, state the research question(s), and tell why the study is needed. Include a full 
description of the study design, methods and procedures. 
 
The Food and Drug Administration (FDA) has reported that severe radiation-induced 
burns have occurred in patients undergoing invasive fluoroscopic procedures, and has 
made recommendations for the avoidance of such x-ray-induced skin injuries.   
 
Typical absorbed dose rates from fluoroscopic x-ray equipment are between 2 and 5 
rad/minute, but can vary greatly depending upon modes of equipment operation, 
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 movement of the x-ray source during the procedure, and patient size.  Radiation injury, 
apparent as early transient erythema, has been observed after absorbed doses to the skin 
of about 200 rad.  Even at typical dose rates, injury to the skin can occur after less than 
one hour of fluoroscopy time.  More severe effects can occur if the fluoroscopy times are 
longer and the subsequent doses larger.   
 
The objective of this project is to evaluate radiation exposures to patients undergoing x-
ray procedures at UNC-Hospitals Electrophysiology (EP) Lab through the collection and 
evaluation of data on fluoroscopic times, which provide the best overall indicator of 
relative absorbed doses to the patient.   
 
A log book of fluoroscopic times utilized during EP procedures that is maintained in the 
UNC-Hospitals EP Lab will be evaluated for this study.  Procedures having fluoroscopy 
times approaching or exceeding 60 minutes will be considered likely high-dose. 
 
2. Where are the data and/or specimens located now?  In paper format in a logbook in 
the EP Lab.  
 
3. The data were originally gathered for:   clinical use     research use      not 
applicable 
 
 The specimens were originally gathered for:   clinical use     research use      
not applicable 
 
Has the purpose for which the specimens were collected been met before removal of any 
excess, as certified by the pathologist in charge or clinical laboratory director?    
  yes   no   not applicable 
 
4. Will the data be recorded and/or specimens labeled using any of the identifiers on 
the following list?   (remember that “Protected Health Information” = health 
information + identifiers)        yes   no     If yes, check all that apply: 
 
 Names 
 Any geographic subdivisions smaller than a State, including street address, city, county, precinct, zip code 
and their equivalent geocodes, except for the initial three digits of a zip code 
 Any elements of dates (except year) for dates directly related to an individual, including birth date, 
admission date, discharge date, date of death.  For ages over 89:  all elements of dates (including year) 
indicative of such age, except that such ages and elements may be aggregated into a single category of age 
90 and older 
 Telephone numbers 
 Fax numbers  
 Electronic mail addresses 
 Social security numbers  
 Medical record numbers  
 Health plan beneficiary numbers  
 Account numbers  
 Certificate/license numbers  
 Vehicle identifiers and serial numbers, including license plate numbers  
 Device identifiers and serial numbers  
 Web universal resource locators (URLS)  
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  Internet protocol (IP) address numbers  
 Biometric identifiers, including finger and voice prints 
 Full face photographic images and any comparable images 
 Any other unique identifying number, characteristic or code, other than dummy identifiers that are not 
derived from actual identifiers and for which the re-identification key is maintained by the health care provider 
and not disclosed to the researcher  
 
If “yes” or any item checked, with whom will Protected Health Information be shared 
during the course of the research? 
   Coordinating Center   Statisticians   Consultants   Other researchers   
Registries 
  Sponsors (listed above)   Labs   Journals   Other: 
____________________________ 
 
5. How will confidentiality be protected?  (must be answered in detail in the space below)  
Since protected health information is not being gathered and included in this project, 
confidentiality will remain protected.  The only identifier in the data (logbook) to be 
analyzed is patient name, which will be removed from the data prior to being 
removed from UNC-Hospitals for analysis. 
 
6. How will data be protected?   (Per UNC Security Policy, data should be stored behind 
at least two of the following safeguards.  Please check all that apply). 
 
For electronic data: 
   Secure network   Password access   
Other:___________________________ 
 
For hardcopy data: 
   Data de-identified by research team (stripped of 18 identifiers listed above)   
Locked suite   Locked office  
   Locked file cabinet   Data coded by research team with a master 
list secured and kept separately   
   
Other:_______________________________________________________________
___ 
 
7. Describe your plan to destroy identifiers. 
The only patient identifier we will have access to is patient name, which will not be 
gathered for use in this project.  Patient names will be removed from the information 
to be analyzed prior to removing from UNC-Hospitals.  Since no identifiers are 
gathered for this project, there will be no identifiers to destroy. 
 
8. When will identifiers be destroyed? 
Identifiers (patient name) will be removed from the information to be analyzed prior 
to removing it from UNC-Hospitals. 
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 9. To justify a waiver of the requirement to seek informed consent and/or HIPAA 
authorization from the subjects, you must be able to answer “YES” to items (a)-(f) 
below.  Insert explanations that support your request for waiver. 
 
a)  Will the research involve no greater than minimal risk to subjects or to their 
privacy?  
  yes    no 
(Minimal risk means that the probability and magnitude of 
harm or discomfort anticipated in the research are not 
greater than those ordinarily encountered in daily life or 
during the  performance of routine physical or 
psychological examinations or tests.) 
      
 
b)  Is it true that the waiver will not adversely affect the rights and welfare of 
subjects? 
  yes    no 
(Consider the right of privacy and possible risk of breach of 
confidentiality in light of the information you wish to 
gather.) 
      
 
c) Is the risk to privacy reasonable in relation to benefits to be gained or the 
importance of the knowledge to be gained? 
  yes    no  
 
d) Would the research be impracticable without the waiver? 
  yes    no 
(If you checked “yes,” explain how the requirement to 
obtain consent would make the research impracticable, e.g. 
are most of the subjects lost to follow-up or deceased?). 
There are hundreds of electrophysiology procedures performed that we will 
analyze the fluoroscopy time of, thus contacting all involved individuals is 
impracticable.   
 
e) Would the research be impracticable if you could not record protected  
health information (PHI)? 
  yes    no 
 (If you checked “yes,” explain how not recording PHI 
would make  the research  impracticable). 
Since no patient identifiers are necessary for this project, we 
will be gathering no such information.  
 
f) When appropriate, do you have plans to provide subjects with pertinent 
information after their participation is over? 
  yes    no  
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 (e.g.  Will you provide details withheld during consent, or 
tell them if you found information with direct clinical 
relevance for the subjects?  This may be an uncommon 
scenario) 
No new information will be learned during this analysis of 
existing records that would be pertinent to the subjects. 
 
 
 
 
 
STATEMENT OF PRINCIPAL INVESTIGATOR: 
I certify that the above information is correct, that it will apply throughout the performance of the 
proposed research and that I will be responsible for safeguarding the confidentiality of the human 
subjects who are involved.  I am aware of the confidential nature of the information obtained for the 
purposes of this research.  No protected health information (PHI) from this research will be shared 
with or disclosed to others, for purposes other than conducting the research as described above.  I will 
vouch for any person other than myself who will work with this information under my direction.  The 
names of these persons are:  
 
__________________________      __________________________        
 
 I agree to a continuing exchange of information with the IRB.  I agree to obtain IRB approval before 
making any changes or additions to the project.  I will provide progress reports at least annually, 
unless this application is determined by the IRB to be exempt from continuing review. 
 
 
Signed _________________________________________  ____________ 
  Principal Investigator         Date 
 
 
_________________________________________  ____________ 
  Faculty advisor, if principal investigator is student   Date 
 
 
For specimens:_________________________________________  ____________ 
  Director of laboratory where specimens are stored   Date 
 
 
Please remember to submit a copy of the Ethics Education Certificate, printed from the 
Research Ethics Training Database, for all investigators and study staff.  See IRB 
website for details. 
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 OFFICE OF HUMAN RESEARCH ETHICS 
Institutional Review Board 
 
APPLICATION FOR IRB APPROVAL OF 
HUMAN SUBJECTS RESEARCH 
Version 19-May-2005 
 
Behav   
IRB Stu
Rec’d 
 Full 
 
Part A.1.  Contact Information, Agreements, and Signatures 
 
Title of Study:  The Use of a Radiochromic Film for the Evaluation of Sk
Extended Fluoroscopy Procedures in an Electrophysiology Lab. 
Date:  May 23, 2005 
 
Name and degrees of Principal Investigator:  James Bradford Taylor, BS 
Department:  Environment Health and Safety Mailing address/CB #:  CB# 16
UNC-CH PID:  702900680 Pager:  216-4564    
Phone #:  962-5727 Fax #:  962-0227 Email Address:  Bradford_T
 
For trainee-led projects: __ undergraduate  X graduate  __ postdoc  __ resident  __
Name of faculty advisor:  Marija Ivanovic, Ph.D. 
Department:  Radiology Mailing address/CB #:  CB# 75
Phone #:  843-0717 Fax #:   Email Address:  MIvanovi@
 
Name, phone number, email address of project manager or coordinator, if any:
 
List all other project personnel including co-investigators, and anyone else who ha
subjects or identifiable data from subjects:  NONE 
 
Name of funding source or sponsor:   
__  not funded   __  Federal   __  State   __  industry   __  foundation   X  UNC-CH 
__  other (specify):           Sponsor or award number:   
 
Include following items with your submission, where applicable.  Check the items b
in order listed. 
□ This application.  One copy must have original PI signatures. 
□ Consent and assent forms, fact or information sheets; include phone and verba
□ HIPAA authorization addendum to consent form 
□ All recruitment materials including scripts, flyers and advertising, letters, ema
□ Questionnaires, scripts used to guide phone or in-person interviews, etc. 
□ Focus group guides 
□ Data use agreements (may be required for use of existing data from third parti
□ Addendum for Multi-Site Studies where UNC-CH is the Lead Coordinating C
□ Documentation of reviews from any other committees (e.g., GCRC, Oncology
□ Documentation of training in human research ethics for all study personnel 
□ Investigator Brochure if a drug study 
□ Protocol, grant application or proposal supporting this submission; (e.g., extra
application to NIH or foundation, industry protocol, student proposal) 
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Principal Investigator:  I will personally conduct or supervise this research study.  I will 
ensure that this study is performed in compliance with all applicable laws, regulations and 
University policies regarding human subjects research.  I will obtain IRB approval before 
making any changes or additions to the project.  I will notify the IRB of any other changes in 
the information provided in this application.  I will provide progress reports to the IRB at 
least annually, or as requested.  I will report promptly to the IRB all unanticipated problems 
or serious adverse events involving risk to human subjects.  I will follow the IRB approved 
consent process for all subjects.  I will ensure that all collaborators, students and employees 
assisting in this research study are informed about these obligations.  All information given 
in this form is accurate and complete.  
 
    
Signature of Principal Investigator Date 
 
Faculty Advisor if PI is a Student or Trainee Investigator:  I accept ultimate 
responsibility for ensuring that this study complies with all the obligations listed above for 
the PI. 
 
    
Signature of Faculty Advisor Date 
 
 
Department or Division Chair, Center Director (or counterpart) of PI:  (or Vice-Chair or 
Chair’s designee if Chair is investigator or otherwise unable to review):  I certify that this 
research is appropriate for this Principal Investigator, that the investigators are qualified to 
conduct the research, and that there are adequate resources (including financial, support and 
facilities) available.  I support this application, and hereby submit it for further review. 
 
    
Signature of Department Chair or designee Date 
 
    
Print Name of Department Chair or designee Department 
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 Part A.2.  Summary Checklist 
 Are the following involved?  Yes No 
A.2.1.  Existing data, research records, patient records, and/or human biological specimens?   __   _x_ 
A.2.2.  Surveys, questionnaires, interviews, or focus groups with subjects?   __   _x_ 
A.2.3.  Videotaping, audiotaping, filming of subjects?   __   _x_ 
A.2.4.  Do you plan to enroll subjects from these vulnerable or select populations: 
a.  UNC-CH students or UNC-CH staff?  .........................................................................
b.  Non-English-speaking?  ...............................................................................................
c.  Decisionally impaired?  ................................................................................................
d.  Patients?  ......................................................................................................................
e.  Prisoners, parolees and other convicted offenders?  ....................................................
f.  Pregnant women?  ........................................................................................................
g.  Minors (less than 18 years)?  If yes, give age range:      to     years  ...........................
 
  __ 
  __ 
  __ 
  _x_ 
  __ 
  __ 
  __ 
 
  _x_ 
  _x_ 
  _x_ 
  __ 
  _x_ 
  _x_ 
  _x_ 
A.2.5.  a.  Is this a multi-site study (i.e., involves organization(s) outside UNC-CH)? 
b.  Will any of these sites be outside the United States? 
If yes, provide contact information for the foreign IRB. 
c.  Is UNC-CH the sponsor or lead coordinating center? 
If yes, include the Addendum for Multi-site Studies where UNC-CH is the Lead 
Coordinating Center. 
  __ 
  __ 
 
  __ 
 
  _x_ 
  __ 
 
  __ 
 
A.2.6.  Will there be a data and safety monitoring committee (DSMB or DSMC)?   __   _x_ 
A.2.7.  a.  Are you collecting sensitive information such as sexual behavior, HIV status, 
recreational drug use, illegal behaviors, child/physical abuse, immigration status, etc? 
b.  Do you plan to obtain a federal Certificate of Confidentiality for this study? 
 
 
  __ 
  __ 
 
 
  _x_ 
  _x_ 
A.2.8.  a.  Investigational drugs?  (provide IND #   )  
b.  Approved drugs for “non-FDA-approved” conditions? 
All studies testing substances in humans must provide a letter of acknowledgement from 
the UNC Health Care Investigational Drug Service (IDS). 
  __ 
  __ 
  _x_ 
  __ 
A.2.9.  Placebo(s)?   __   _x_ 
A.2.10.  Investigational devices, instruments, machines, software?  (provide IDE #  )   __   _x_ 
A.2.11.  Fetal tissue?   __   _x_ 
A.2.12.  Genetic studies on subjects’ specimens?   __   _x_ 
A.2.13.  Storage of subjects’ specimens for future research? 
 If yes, see instructions within the form Consent for Stored Samples.    __   _x_ 
A.2.14.  Diagnostic or therapeutic ionizing radiation, or radioactive isotopes, which subjects 
would not receive otherwise? 
 If yes, approval by the UNC-CH Radiation Safety Committee is required. 
  __ 
   
  _x_ 
   
A.2.15.  Recombinant DNA or gene transfer to human subjects? 
 If yes, approval by the UNC-CH Institutional Biosafety Committee is required.   __   _x_ 
A.2.16.  Does this study involve UNC-CH cancer patients? 
 If yes, submit this application directly to the Oncology Protocol Review Committee.   __   _x_ 
A.2.17.  Will subjects be studied in the General Clinical Research Center (GCRC)? 
 If yes, obtain the GCRC Addendum from the GCRC and submit complete application 
(IRB application and Addendum) to the GCRC. 
  __   _x_ 
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 Part A.3.  Potential Conflict of Interest 
 
The following questions apply to all investigators and study staff involved with this 
research, and/or their immediate family members (spouse, dependent children, parents, 
significant others).  With respect to this study, will any of the study investigators or study 
staff or their immediate family members:   
 
A.3.1.  Have an intellectual property interest in any technology or 
invention used in this study, including patent rights, copyright, etc.? __  yes _x_  no 
A.3.2.  Receive support from a non-UNC source (other than through 
a sponsored research agreement) for this research study? __  yes _x_  no 
A.3.3.  Receive any form of personal compensation (other than as 
specified in the budget of a sponsored research agreement) from a 
Sponsor of this study, including salary, consulting fees, honoraria, 
royalties, equipment, gifts, etc.? 
a.  If yes, does or will that personal compensation exceed 
$10,000? 
b.  If yes, is that personal compensation tied to any performance 
within this study such as enrollment goals for the study? 
 
 
 
__  yes 
__  yes 
 
__  yes 
 
 
 
_x_  no 
__  no 
 
__  no 
A.3.4.  Have an ownership interest of any nature in the Sponsor or a 
product used in this study, including equity, stock options, etc? 
a.  If yes, does or will that interest exceed $10,000 in value or 5% 
equity in a publicly traded Sponsor? 
b.  If yes, does that interest include any equity interest in a non-
publicly traded Sponsor? 
 
__  yes 
 
__  yes 
 
__  yes 
 
_x_  no 
 
__  no 
 
__  no 
A.3.5.  Hold any position with the Sponsor, including officer, 
employee, director, trustee, consultant, member of advisory board, 
etc.? 
__  yes _x_  no 
A.3.6.  Have a conflict of interest previously disclosed through the 
University’s conflict of interest evaluation process that relates to this 
research study? 
__  yes _x_  no 
 
If the answer is “yes” to any of the questions above, please include an explanation with this 
application.  As with any changes to the research itself, relationships or interests that develop 
later should be brought to the attention of the IRB for further consideration.  Please contact 
the Office of University Counsel for guidance or assistance regarding the University’s 
Conflict of Interest Policy.  See http://www.unc.edu/campus/policies/coi.html for the policy. 
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 Part A.4.  Questions Common to All Studies 
 
For all questions, if the study involves only secondary data analysis, focus on your proposed design, 
methods and procedures, and not those of the original study that produced the data you plan to use. 
 
A.4.1.  Brief Summary.  Provide a brief non-technical description of the study, which will be used 
for internal and external communications regarding this research.  Include purpose, methods, and 
participants.  Typical summaries are 50-100 words. 
The purpose of this study is simple.  We will monitor patients undergoing high radiation dose 
procedures in the Electrophysiology Lab of UNC-Hospitals.  Dose to the patients skin will be 
monitored using an x-ray sensitive film that will be placed beneath the patient on top of the table that 
the patient lies on for the procedure.  Participants will be those patients undergoing a clinically 
necessary Electrophysiology procedure. 
 
A.4.2.  Purpose and Rationale.  Provide a summary of the background information, state the 
research question(s), and tell why the study is needed.  If a complete rationale and literature review 
are in an accompanying grant application or other type of proposal, only provide a brief summary 
here.  If there is no proposal, provide a more extensive rationale and literature review. 
The Food and Drug Administration (FDA) has reported that severe radiation-induced burns have 
occurred in patients undergoing invasive fluoroscopic procedures, and has made recommendations for 
the avoidance of such x-ray-induced skin injuries.   
 
Typical absorbed dose rates from fluoroscopic x-ray equipment are between 2 and 5 rad/minute, but 
can vary greatly depending upon modes of equipment operation, movement of the x-ray source during 
the procedure, and patient size.  Radiation injury, apparent as early transient erythema, has been 
observed after absorbed doses to the skin of about 200 rad.  Even at typical dose rates, injury to the 
skin can occur after less than one hour of fluoroscopy time.  More severe effects can occur if the 
fluoroscopy times are longer and the subsequent doses larger.   
 
The primary objective of this project is to evaluate radiation dose to patients undergoing extended x-
ray procedures at UNC-Hospitals Electrophysiology Lab (EP).  Those EP procedures associated with 
likely high-doses have been determined using information collected and analyzed in the IRB-
approved study titled “Identification of Likely High Radiation Dose Procedures through the 
Evaluation of Fluoroscopic Times in an Electrophysiology Lab”. 
 
Until now, we have only estimated dose to patients, but this study will allow us to directly measure 
radiation dose using a wide-area dosimetry film described below.  Determining actual dose will allow 
us to better evaluate the risk to patients undergoing extended fluoroscopy EP procedures.  The results 
of the dosimetry film will be used to correlate patient skin dose with fluoroscopy time, patient weight, 
and patient body mass index (BMI).  We hope to determine which of these variables are better at 
predicting radiation dose and risk. 
 
Using knowledge gained from this study, we hope to be able to providing physicians with the 
information necessary to make informed decisions concerning the management of high-dose 
procedures, determine the need for any dose-reduction measures necessary for high-dose procedures, 
and assist with demonstrating compliance with FDA Public Health Advisories and proposed rule 
changes in the NC Regulations for Protection Against Radiation. 
 
A.4.3.  Full description of the study design, methods and procedures.  Describe the research 
study.  Discuss the study design; study procedures; sequential description of what subjects will be 
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 asked to do; assignment of subjects to various arms of the study if applicable; doses; frequency and 
route of administration of medication and other medical treatment if applicable; how data are to be 
collected (questionnaire, interview, focus group or specific procedure such as physical examination, 
venipuncture, etc.).  Include information on who will collect data, who will conduct procedures or 
measurements.  Indicate the number and duration of contacts with each subject; outcome 
measurements; and follow-up procedures.  If the study involves medical treatment, distinguish 
standard care procedures from those that are research.  If the study is a clinical trial involving patients 
as subjects and use of placebo control is involved, provide justification for the use of placebo 
controls.   
Variables to be recorded during each procedure include date of procedure, and demographic details of 
the patient such as age, sex, height and weight, procedure category (i.e. ablation), nature of procedure 
(i.e. atrial flutter), physician, fluoroscopic time, success or failure of the procedure, and operating 
characteristics of the equipment such as continuous vs. specific pulse rate, phosphor size used, and 
SID variability.   
 
The dose measurements will be performed using a wide-area radiochromic dosimetry film, 
specifically designed to measure skin dose during fluoroscopically-guided x-ray procedures.  The film 
will be placed on the table between the patient and x-ray tube.  The film will be placed immediately 
adjacent to the patient and will effectively record the skin dose.  The film will not be apparent by the 
patient and will not interfere with the fluoroscopic image or procedure in any way.   
 
These radiochromic films were developed to measure low-energy photons (<200 keV) and has a 
range of energy independence from 60-120 keV (the diagnostic energy range used in the 
Electrophysiology Lab).  The film is supplied in 14”x17” sheets, and may be cut down to smaller 
sizes for more efficient use.  The film is self-developing, requires no chemicals, and is unaffected by 
water, blood and other aqueous fluids.  The dose to the patient is determined by reading the maximum 
optical density present on the film after the procedure with a densitometer or flatbed scanner. 
 
A.4.4.  Benefits to subjects and/or society.  Describe any potential for direct benefit to individual 
subjects, as well as the benefit to society based on scientific knowledge to be gained; these should be 
clearly distinguished.  Consider the nature, magnitude, and likelihood of any direct benefit to 
subjects.  If there is no direct benefit to the individual subject, say so here and in the consent form (if 
there is a consent form).  Do not list monetary payment or other compensation as a benefit. 
Knowledge gained from this study will assist with development of an effective program for the safe 
use of fluoroscopic x-ray which will serve to provide physicians the information necessary to make 
informed decisions concerning the management of future high-dose procedures.   
 
A.4.5.  Full description of risks and measures to minimize risks.  Include risk of psychosocial 
harm (e.g., emotional distress, embarrassment, breach of confidentiality), economic harm (e.g., loss of 
employment or insurability, loss of professional standing or reputation, loss of standing within the 
community) and legal jeopardy (e.g., disclosure of illegal activity or negligence), as well as known 
side effects of study medication, if applicable, and risk of pain and physical injury.  Describe what 
will be done to minimize these risks.  Describe procedures for follow-up, when necessary, such as 
when subjects are found to be in need of medical or psychological referral.  If there is no direct 
interaction with subjects, and risk is limited to breach of confidentiality (e.g., for existing data), state 
this. 
There are no risks to the subjects associated with this study. 
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 A.4.6.  Data analysis.  Tell how the qualitative and/or quantitative data will be analyzed.  Explain 
how the sample size is sufficient to achieve the study aims.  This might include a formal power 
calculation or explanation of why a small sample is sufficient (e.g., qualitative research, pilot studies). 
Since the primary purpose of this study is to evaluate fluoroscopic times and measure peak skin 
doses, only simple statistics will be necessary.  
 
A.4.7.  Will you collect or receive any of the following identifiers as part of the study data?  
Does not apply to consent forms. 
 
 __  No    _x_  Yes    If yes, check all that apply: 
 
a. __ Names 
b. __ Telephone numbers   
c. _x_ Any elements of dates (other than 
year) for dates directly related to an 
individual, including birth date, 
admission date, discharge date, date of 
death.  For ages over 89:  all elements of 
dates (including year) indicative of such 
age, except that such ages and elements 
may be aggregated into a single category 
of age 90 and older 
d. __ Any geographic subdivisions smaller 
than a State, including street address, city, 
county, precinct, zip code and their 
equivalent geocodes, except for the initial 
three digits of a zip code 
e. __ Fax numbers  
f. __ Electronic mail addresses 
g. __ Social security numbers  
h. __ Medical record numbers 
i. __ Health plan beneficiary numbers 
j. __ Account numbers  
k. __ Certificate/license numbers  
l. __ Vehicle identifiers and serial numbers 
(VIN), including license plate numbers  
m. __ Device identifiers and serial numbers 
(e.g., implanted medical device) 
n. __ Web universal resource locators 
(URLs)  
o. __ Internet protocol (IP) address 
numbers  
p. __ Biometric identifiers, including finger 
and voice prints 
q. __ Full face photographic images and 
any comparable images 
r. __ Any other unique identifying number, 
characteristic or code, other than dummy 
identifiers that are not derived from actual 
identifiers and for which the re-
identification key is maintained by the 
health care provider and not disclosed to 
the researcher 
A.4.8.  Data sharing.  With whom will identifiable (contains any of the 18 identifiers listed in 
question 7 above) data be shared outside the immediate research team?  For each, explain 
confidentiality measures.  Include data use agreements, if any. 
 
 _x_  No one 
 __  Coordinating Center:   
 __  Statisticians:   
 __  Consultants:   
 __  Other researchers:   
 __  Registries:   
 __  Sponsors:   
 __  External labs for additional testing:   
 __  Journals:   
 __  Publicly available dataset:   
 __  Other:   
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 A.4.9.  Confidentiality of the data.  Describe procedures for maintaining confidentiality of the data 
you will collect or will receive.  Describe how you will protect the data from access by those not 
authorized.  How will data be transmitted among research personnel?  Where relevant, discuss the 
potential for deductive disclosure (i.e., directly identifying subjects from a combination of indirect 
IDs).  Describe your plan to destroy identifiers.  When will identifiers be destroyed? 
Data collected, including date of the procedure monitored, will be kept in a locked file drawer in the 
PI’s office in the Department of Environment, Health and Safety.  This office is also kept locked 
after-hours.  Identifiers will be shredded once the research is complete and the information is no 
longer necessary.  
 
A.4.10.  Data security for storage and transmission.  Please check all that apply. 
 
For electronic data: 
 _x_  Secure network _x_  Password access __  Encryption  
 __  Other (describe):   
 __  Portable storage (e.g., laptop computer, flash drive) 
 Describe how data will be protected for any portable device:   
 
For hardcopy data (including human biological specimens, CDs, tapes, etc.): 
 __  Data de-identified by research team (stripped of the 18 identifiers listed in question 7 above) 
 _x_  Locked suite or office 
 _x_  Locked cabinet  
 __  Data coded by research team with a master list secured and kept separately 
 __  Other (describe):   
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 Part A.5.  The Consent Process and Consent Documentation (including 
Waivers) 
 
The standard consent process is for all subjects to sign a document containing all the elements of 
informed consent, as specified in the federal regulations.  Some or all of the elements of consent, 
including signatures, may be altered or waived under certain circumstances. 
 
• If you will obtain consent in any manner, complete section A.5.1. 
• If you are obtaining consent, but requesting a waiver of the requirement for a signed consent 
document, complete section A.5.2. 
• If you are requesting a waiver of any or all of the elements of consent, complete section A.5.3. 
 
You may need to complete more than one section.  For example, if you are conducting a phone 
survey with verbal consent, complete sections A.5.1, A.5.2, and possibly A.5.3. 
 
A.5.1.  Describe the process of obtaining informed consent from subjects.  If children will be 
enrolled as subjects, describe the provisions for obtaining parental permission and assent of the child.  
If decisionally impaired adults are to be enrolled, describe the provision for obtaining surrogate 
consent from a legally authorized representative (LAR).  If non-English speaking people will be 
enrolled, explain how consent in the native language will be obtained.  Address both written 
translation of the consent and the availability of oral interpretation.  After you have completed this 
part A.5.1, if you are not requesting a waiver of any type, you are done with Part A.5.; proceed to 
Part B. 
Informed consent will not be obtained, but the subjects will be provided with an information sheet 
which provides details about their involvement in the study.  See section A.5.3. 
 
A.5.2.  Justification for a waiver of written (i.e., signed) consent.  The default is for subjects to sign 
a written document that contains all the elements of informed consent.  Under limited circumstances, 
the requirement for a signed consent form may be waived by the IRB if either of the following is true: 
 
a.  The only record linking the subject and the research would be the consent 
document and the principal risk would be potential harm resulting from a breach 
of confidentiality (e.g., study involves sensitive data that could be damaging if 
disclosed). 
Explain.   
 
b.  The research presents no more than minimal risk of harm to subjects and 
involves no procedures for which written consent is normally required outside of 
the research context (e.g., phone survey). 
Explain.   
 
If you checked “yes” to either, will consent be oral?  Will you give out a fact 
sheet?  Use an online consent form, or include information as part of the survey 
itself, etc?  
__  yes  __  no 
 
 
 
 
 
__  yes  __  no 
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A.5.3.  Justification for a full or partial waiver of consent.  The default is for subjects to sign a 
written document that contains all the elements of informed consent.  A waiver might be requested for 
research involving only existing data or human biological specimens (see also Part C).  More rarely, it 
might be requested when the research design requires withholding some study details at the outset 
(e.g., behavioral research involving deception).  In limited circumstances, parental permission may be 
waived.  This section should also be completed for a waiver of HIPAA authorization if research 
involves Protected Health Information (PHI) subject to HIPAA regulation, such as patient records. 
 
 __  Requesting waiver of some elements (specify; see SOP 28 on the IRB web site):   
 _x_  Requesting waiver of consent entirely 
If you check either of the boxes above, answer items a-f..  To justify a full waiver of the 
requirement for informed consent, you must be able to answer “yes” (or “not applicable” for 
question c) to items a-f.  Insert brief explanations that support your answers. 
 
a.  Will the research involve no greater than minimal risk to subjects or to their 
privacy? 
Explain.  We are simply placing a piece of thin film beneath the patient during 
their procedure.  The patient will not notice the film and the film will not 
interfere with their procedure in any way.  There is no risk to the patient. 
_x_  yes  __  no 
 
b.  Is it true that the waiver will not adversely affect the rights and welfare of 
subjects?  (Consider the right of privacy and possible risk of breach of 
confidentiality in light of the information you wish to gather.) 
Explain.  The subjects will notice nothing or be exposed to any additional risk 
related to this study.  They would have their Electrophysiology procedure 
performed in the same manner regardless of this study being conducted. 
_x_  yes  __  no 
 
c.  When applicable to your study, do you have plans to provide subjects with 
pertinent information after their participation is over?  (e.g., Will you provide 
details withheld during consent, or tell subjects if you found information with 
direct clinical relevance?  This may be an uncommon scenario.) 
Explain.   
__  yes  _x_  not 
applicable 
 
 
d.  Would the research be impracticable without the waiver?  (If you checked 
“yes,” explain how the requirement to obtain consent would make the research 
impracticable, e.g., are most of the subjects lost to follow-up or deceased?).  
Explain.  There is no risk to the patient from this study.  Taking the additional 
time to receive consent would be an unnecessary requirement for this study 
which simply involves placing a piece of film underneath them.  
_x_  yes  __  no 
 
e.  Is the risk to privacy reasonable in relation to benefits to be gained or the 
importance of the knowledge to be gained? 
Explain.  The risk to patient privacy is very small, and we have procedures for 
maintaining identifiable data, such as date, confidential.  There is great benefit to 
measuring and knowing radiation skin doses for patients undergoing 
Electrophysiology procedures that relate to the development of a program for 
managing such high-dose fluoroscopy procedures. 
_x_  yes  __  no 
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 If you are accessing patient records for this research, you must also be able to answer “yes” to 
item f to justify a waiver of HIPAA authorization from the subjects. 
 
f.  Would the research be impracticable if you could not record (or use) Protected 
Health Information (PHI)?  (If you checked “yes,” explain how not recording or 
using PHI would make the research impracticable). 
Explain.  It would be impracticable to coordinate scheduling of the dose 
monitoring if I were not allowed to access, know, or otherwise use the procedure 
date. 
_x_  yes  __  no 
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 Part B. Questions for Studies that Involve Direct Interaction with Human 
Subjects 
 →  If this does not apply to your study, do not submit this section. 
 
B.1.  Subjects.  Specify number, gender, ethnicity, race, and age.  Specify whether subjects are 
healthy volunteers or patients.  If patients, specify any relevant disease or condition and indicate how 
potential subjects will be identified. 
This study involves the estimation and measuring of radiation dose to patients 18 years or older who 
are undergoing a clinically necessary electrophysiology procedure.  Monitoring will be performed on 
up to 50 subjects.  Participation is not age, gender, ethnicity, or pregnancy dependent.   
 
B.2.  Inclusion/exclusion criteria.  List required characteristics of potential subjects, and those that 
preclude enrollment.  Justify exclusion of any group, especially by criteria based on gender, ethnicity, 
race, or age.  If pregnant women are excluded, or if women who become pregnant are withdrawn, 
specific justification must be provided. 
Subjects will be eligible for inclusion in the dose estimation and measuring part of the study if their 
clinical care requires undergoing an electrophysiology procedure identified as likely high-dose. 
 
B.3.  Methods of recruiting.  Describe how and where subjects will be identified and recruited.  
Indicate who will do the recruiting, and tell how subjects will be contacted.  Describe efforts to ensure 
equal access to participation among women and minorities.  Describe how you will protect the 
privacy of potential subjects during recruitment.  For prospective subjects whose status (e.g., as 
patient or client), condition, or contact information is not publicly available (e.g., from a phone book 
or public web site), the initial contact should be made with legitimate knowledge of the subjects’ 
circumstances.  Ideally, the individual with such knowledge should seek prospective subjects’ 
permission to release names to the PI for recruitment.  Alternatively, the knowledgeable individual 
could provide information about the study, including contact information for the investigator, so that 
interested prospective subjects can contact the investigator.  Provide the IRB with a copy of any 
document or script that will be used to obtain the patients’ permission for release of names or to 
introduce the study.  Check with your IRB for further guidance. 
Prospective subjects will be approached initially by their electrophysiology physician performing the 
procedure about participation in this project.  Subjects will be provided with an information sheet 
which provides details about their involvement in the study.   
 
B.4.  Protected Health Information (PHI).  If you need to access Protected Health Information 
(PHI) to identify potential subjects who will then be contacted, you will need a limited waiver of 
HIPAA authorization.  If this applies to your study, please provide the following information. 
 
a. Will the information collected be limited only to that necessary to contact the subjects to ask if 
they are interested in participating in the study?   
 I will call or otherwise contact the Electrophysiology Lab to learn of the dates that high dose 
 procedures are being performed in order to coordinate monitoring.  The Lab may also contact me 
 with the date and time that high dose procedures are scheduled for. 
 
b. How will confidentiality/privacy be protected prior to ascertaining desire to participate?   
 Neither subject name nor any other PHI (with the exception of procedure date) will be known.   
 
c. When and how will you destroy the contact information if an individual declines participation?   
 Not applicable to this project. 
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B.5.  Duration of entire study and duration of an individual subject’s participation, including 
follow-up evaluation if applicable.  Include the number of required contacts and approximate 
duration of each contact. 
A subject’s participation in this study is only for the duration of the time necessary to complete their 
clinical electrophysiology procedure. 
 
B.6.  Where will the subjects be studied?  Describe locations where subjects will be studied, both 
on and off the UNC-CH campus. 
Subjects will be studied in UNC-Hospitals Electrophysiology Lab. 
 
B.7.  Privacy.  Describe procedures that will ensure privacy of the subjects in this study.  Examples 
include the setting for interviews, phone conversations, or physical examinations; communication 
methods or mailed materials (e.g., mailings should not indicate disease status or focus of study on the 
envelope). 
We will not know any subject identifiers other than the date of the procedure.  This information will 
be kept secured and available only to the immediate research team. 
 
B.8.  Inducements for participation.  Describe all inducements to participate, monetary or non-
monetary.  If monetary, specify the amount and schedule for payments and how this will be prorated 
if the subject withdraws (or is withdrawn) from the study prior to completing it.  For compensation in 
foreign currency, provide a US$ equivalent.  Provide evidence that the amount is not coercive (e.g., 
describe purchasing power for foreign countries).  Include food or refreshments that may be provided. 
Not applicable to this project. 
 
B.9.  Costs to be borne by subjects.  Include child care, travel, parking, clinic fees, diagnostic and 
laboratory studies, drugs, devices, all professional fees, etc.  If there are no costs to subjects other 
than their time to participate, indicate this. 
There are no costs to the subjects associated with this research. 
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 Part C. Questions for Studies using Data, Records or Human Biological 
Specimens without Direct Contact with Subjects 
 →  If this does not apply to your study, do not submit this section. 
 
C.1.  What records, data or human biological specimens will you be using?  (check all that apply): 
 
 __ Data already collected for another research study 
 __ Data already collected for administrative purposes (e.g., Medicare data, hospital discharge 
data) 
 __ Medical records (custodian may also require form, e.g., HD-974 if UNC-Health Care System) 
 __ Electronic information from clinical database (custodian may also require form) 
 __ Patient specimens (tissues, blood, serum, surgical discards, etc.) 
 __ Other (specify):   
 
C.2.  For each of the boxes checked in 1, how were the original data, records, or human biological 
specimens collected?  Describe the process of data collection including consent, if applicable. 
 
C.3.  For each of the boxes checked in 1, where do these data, records or human biological specimens 
currently reside? 
 
C.4.  For each of the boxes checked in 1, from whom do you have permission to use the data, records 
or human biological specimens?  Include data use agreements, if required by the custodian of data 
that are not publicly available. 
 
C.5.  If the research involves human biological specimens, has the purpose for which they were 
collected been met before removal of any excess?  For example, has the pathologist in charge or the 
clinical laboratory director certified that the original clinical purpose has been satisfied?  Explain if 
necessary. 
 
__  yes     __  no      __  not applicable (explain)      
 
C.6.  Do all of these data records or specimens exist at the time of this application?  If not, explain 
how prospective data collection will occur. 
 
__  yes      __  no      If no, explain   
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 Appendix C 
IRB Subject Information Sheet 
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 Appendix D 
Documentation of Required Training
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 Appendix E 
Fluoroscopy Time Log 
 
DATE PHYSICIAN CODE 
TOTAL FLUOROSCOPY 
MINUTES ASSIGNED PROCEDURE CODE 
3/27/2003 C 4 PM 
3/28/2003 C 50 ABL 
4/1/2003 C 4 EPS 
4/4/2003 C 29 ABL 
4/7/2003 A 4 PM 
4/7/2003 A 62 BIV  
4/10/2003 A 13 BIV  
4/11/2003 C 50 BIV  
4/14/2003 A 36 BIV  
4/17/2003 A 25 PM 
4/21/2003 A 9 PM 
4/21/2003 A 17 PM 
4/22/2003 C 5 EPS 
4/22/2003 C 8 ICD 
4/23/2003 C 22 ABL 
4/24/2003 C 8 ICD 
4/24/2003 A 3 CO 
4/25/2003 C 1 ABL 
4/28/2003 A 1 CO 
4/29/2003 C 12 ICD 
4/29/2003 C 61 ICD 
4/30/2003 A 9 PM 
5/1/2003 A 2 EPS 
5/1/2003 A 76 BIV  
5/2/2003 C 8 PM 
5/7/2003 A 9 PM 
5/7/2003 A 46 BIV 
5/8/2003 A 1 CO 
5/8/2003 A 1 CO 
5/8/2003 A 1 CO 
5/12/2003 A 4 PM 
5/12/2003 A 5 ICD 
5/12/2003 A 6 ICD 
5/12/2003 A 12 PM 
5/21/2003 NOT AVAILABLE 1 CO 
5/21/2003 NOT AVAILABLE 9 ICD 
5/28/2003 NOT AVAILABLE 6 PM 
6/2/2003 NOT AVAILABLE 9 PM 
6/2/2003 NOT AVAILABLE 9 PM 
6/2/2003 NOT AVAILABLE 87 BIV  
6/4/2003 NOT AVAILABLE 1 CO 
6/4/2003 NOT AVAILABLE 16 PM 
6/4/2003 NOT AVAILABLE 59 BIV  
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 DATE PHYSICIAN CODE 
TOTAL FLUOROSCOPY 
MINUTES ASSIGNED PROCEDURE CODE 
NOT AVAILABLE 6/6/2003 9 ABL 
NOT AVAILABLE 6/6/2003 10 ICD 
6/9/2003 NOT AVAILABLE 121 BIV  
6/11/2003 NOT AVAILABLE 7 PM 
6/11/2003 NOT AVAILABLE 33 ABL 
6/12/2003 NOT AVAILABLE 20 PM 
6/13/2003 NOT AVAILABLE 13 PM 
6/16/2003 NOT AVAILABLE 8 ICD 
6/16/2003 NOT AVAILABLE 80 BIV  
6/17/2003 NOT AVAILABLE 6 ICD 
6/17/2003 NOT AVAILABLE 62 ABL 
6/25/2003 NOT AVAILABLE 15 PM 
12/3/2003 B 54 BIV  
12/4/2003 A 7 PM 
12/5/2003 B 17 PM 
12/8/2003 A 121 BIV  
12/9/2003 B 7 EPS 
12/10/2003 B 28 ABL 
12/10/2003 B 29 ABL 
12/11/2003 A 40 BIV  
12/15/2003 A 1 CO 
12/15/2003 A 10 EPS 
12/17/2003 B 28 ABL 
12/19/2003 B 18 PM 
12/19/2003 B 36 ABL 
12/22/2003 A 86 ABL 
12/29/2003 B 15 PM 
12/29/2003 B 23 ICD 
12/30/2003 B 8 PM 
12/31/2003 B 33 PM 
1/7/2004 A 80 ABL 
1/12/2004 A 1 CO 
1/12/2004 A 1 CO 
1/16/2004 B 6 ICD 
1/16/2004 B 9 PM 
1/20/2004 B 1 ICD 
1/20/2004 B 13 PM 
1/22/2004 A 22 BIV  
1/23/2004 B 5 ICD 
1/23/2004 B 9 EPS 
1/28/2004 A 12 PM 
1/30/2004 B 9 PM 
2/5/2004 A 2 CO 
2/5/2004 A 19 PM 
2/6/2004 A 23 ICD 
2/9/2004 n/a 34 PM 
2/10/2004 B 12 PM 
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 DATE PHYSICIAN CODE 
TOTAL FLUOROSCOPY 
MINUTES ASSIGNED PROCEDURE CODE 
2/10/2004 B 25 ABL 
2/11/2004 A 4 PM 
2/11/2004 A 100 ABL 
2/12/2004 A 7 PM 
2/12/2004 A 15 PM 
2/13/2004 B 87 ABL 
2/15/2004 A 34 PM 
2/17/2004 B 10 EPS 
2/17/2004 A 23 BIV  
2/18/2004 B 7 ICD 
2/18/2004 B 58 BIV  
2/19/2004 B 48 ICD 
2/20/2004 B 9 PM 
2/20/2004 B 102 ABL 
2/23/2004 B 28 ICD 
2/25/2004 A 25 ABL 
2/26/2004 A 1 CO 
2/26/2004 A 10 PM 
3/1/2004 A 13 PM 
3/2/2004 A 45 BIV  
3/3/2004 B 36 ABL 
3/4/2004 A 1 CO 
3/4/2004 A 5 PM 
3/5/2004 A 140 ABL 
3/9/2004 B 11 PM 
3/11/2004 A 1 CO 
3/15/2004 B 17 PM 
3/15/2004 A 7 PM 
3/15/2004 A 9 ICD 
3/16/2004 B 7 ICD 
3/19/2004 A 53 BIV  
3/20/2004 B 11 ICD 
4/29/2004 B 44 ABL 
4/30/2004 A 1 CO 
4/30/2004 A 56 ICD 
5/1/2004 B 112 ABL 
5/3/2004 B 1 CO 
5/3/2004 A 4 PM 
5/3/2004 A 7 PM 
5/4/2004 B 37 BIV  
5/5/2004 B 5 CO 
5/5/2004 A 39 CO 
5/6/2004 A 3 CO 
5/6/2004 A 3 PM 
5/13/2004 A 1 CO 
5/13/2004 A 1 CO 
5/13/2004 A 2 CO 
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 DATE PHYSICIAN CODE 
TOTAL FLUOROSCOPY 
MINUTES ASSIGNED PROCEDURE CODE 
5/14/2004 B 192 ABL 
5/17/2004 A 1 CO 
5/17/2004 A 6 ICD 
5/17/2004 A 11 PM 
5/18/2004 B 46 BIV  
5/19/2004 B 41 ABL 
5/20/2004 B 8 ICD 
5/20/2004 B 38 BIV  
5/21/2004 B 6 PM 
5/21/2004 B 15 PM 
5/24/2004 A 7 CO 
5/24/2004 A 9 ICD 
5/24/2004 A 12 PM 
5/25/2004 B 1 CO 
5/25/2004 B 4 CO 
5/26/2004 A 10 EPS 
5/27/2004 A 4 ICD 
5/27/2004 A 20 ICD 
5/28/2004 B 18 BIV  
6/1/2004 B 3 ICD 
6/2/2004 A 5 ABL 
6/2/2004 A 15 CO 
6/3/2004 A 1 CO 
6/3/2004 A 6 ICD 
6/4/2004 B 38 ABL 
6/7/2004 A 26 BIV  
6/8/2004 B 10 ICD 
6/8/2004 B 21 ICD 
6/9/2004 B 129 ABL 
6/10/2004 A 10 PM 
6/10/2004 A 10 PM 
6/10/2004 A 14 ICD 
6/10/2004 A 19 PM 
6/11/2004 B 131 ABL 
6/14/2004 A 4 PM 
6/14/2004 A 16 PM 
6/14/2004 A 24 BIV  
10/13/2004 B 9 EPS 
10/13/2004 B 22 ICD 
10/14/2004 B 12 ICD 
10/14/2004 B 16 EPS 
10/18/2004 A 17 PM 
10/20/2004 A 58 ABL 
10/21/2004 A 5 PM 
10/21/2004 A 24 ICD 
10/22/2004 B 33 PM 
10/25/2004 A 58 EPS 
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 DATE PHYSICIAN CODE 
TOTAL FLUOROSCOPY 
MINUTES ASSIGNED PROCEDURE CODE 
10/26/2004 A 3 CO 
10/27/2004 B 23 ICD 
10/28/2004 A 14 CO 
11/4/2004 A 2 PM 
11/4/2004 A 3 PM 
11/5/2004 B 12 ICD 
11/5/2004 B 13 EPS 
11/8/2004 A 3 CO 
11/11/2004 A 14 ICD 
11/15/2004 A 15 ICD 
11/16/2004 B 22 EPS 
11/17/2004 B 171 ABL 
11/18/2004 B 47 BIV  
11/22/2004 A 5 ICD 
11/22/2004 A 12 ICD 
11/23/2004 B 18 ICD 
11/24/2004 B 46 PM 
11/30/2004 B 20 PM 
12/2/2004 A 1 CO 
12/2/2004 A 8 CO 
12/2/2004 A 29 BIV  
12/3/2004 B 45 ICD 
12/6/2004 A 1 CO 
12/6/2004 A 20 ICD 
12/6/2004 A 28 CO 
12/8/2004 B 58 ABL 
12/9/2004 A 25 BIV  
12/10/2004 B 7 ICD 
12/13/2004 A 9 ICD 
12/14/2004 B 1 CO 
12/14/2004 B 53 PM 
12/16/2004 A 1 CO 
12/16/2004 A 1 CO 
12/16/2004 A 16 ICD 
12/20/2004 A 4 CO 
2/28/2005 A 1 CO 
2/28/2005 A 5 ICD 
2/28/2005 A 5 PM 
3/2/2005 A 9 PM 
3/3/2005 A 1 CO 
3/4/2005 A 1 CO 
3/4/2005 A 81 BIV  
3/7/2005 A 1 CO 
3/9/2005 A 26 ABL 
3/10/2005 A 2 CO 
3/10/2005 A 16 ICD 
3/11/2005 A 4 PM 
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 DATE PHYSICIAN CODE 
TOTAL FLUOROSCOPY 
MINUTES ASSIGNED PROCEDURE CODE 
3/11/2005 A 11 PM 
3/14/2005 A 7 ICD 
3/16/2005 A 5 CO 
3/17/2005 A 5 ICD 
3/18/2005 A 19 ICD 
3/21/2005 A 10 PM 
3/21/2005 A 20 ICD 
3/22/2005 A 45 ABL 
3/23/2005 A 9 CO 
3/23/2005 A 9 ICD 
3/24/2005 A 21 PM 
3/28/2005 A 2 ICD 
3/28/2005 A 11 ICD 
3/28/2005 A 19 PM 
3/30/2005 A 10 PM 
3/30/2005 A 17 PM 
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 Appendix F 
Daily Test Pattern Information – Including Measured Red Channel Pixel Values and 
Coefficient of Variation 
 
Scanner 
Station Date Orientation 
Area 
(1) 
Area 
(2) 
Area 
(3) 
Area 
(4) 
Area 
(5) 
Area 
(6) 
Area 
(7) 
Area 
(8) 
1 08/17/2005 Standard 212.19 121.28 52.26 26.29 213.75 122.88 52.83 26.85 
1 08/22/2005 Standard 211.99 121.12 52.29 26.17 213.75 122.91 52.86 26.77 
1 08/25/2005 Standard 213.10 121.38 52.10 26.47 214.83 122.60 52.42 26.52 
1 08/30/2005 Standard 212.51 120.23 52.16 25.51 214.92 121.62 52.19 25.69 
1 09/06/2005 Standard 212.07 120.08 51.76 25.95 214.05 121.56 52.17 25.99 
1 09/12/2005 Standard 212.10 120.28 51.32 24.98 214.12 122.18 51.75 25.31 
1 09/15/2005 Standard 212.81 120.72 52.49 26.02 214.79 122.73 52.88 26.34 
1 09/26/2005 Standard 212.52 120.54 51.57 25.01 214.26 122.29 51.05 25.43 
1 09/28/2005 Standard 212.09 120.08 51.80 24.88 214.37 121.55 52.00 25.05 
4 08/17/2005 Standard 213.49 120.86 51.69 25.51 214.53 122.05 52.28 26.01 
4 08/17/2005 Standard 213.41 120.78 51.62 25.41 214.05 121.88 52.10 25.87 
4 08/17/2005 Upside down 211.71 120.33 51.97 25.86 214.45 121.58 51.92 25.79 
4 08/22/2005 Standard 212.85 120.80 51.62 25.79 213.83 121.94 52.26 26.08 
1 10/17/2005 Standard 212.11 120.17 51.51 25.10 213.94 121.93 51.89 25.32 
1 10/17/2005 Upside down 210.50 119.43 51.89 25.11 214.23 122.22 51.95 25.51 
1 10/17/2005 Upside down 210.43 119.56 51.82 25.15 214.44 122.32 51.96 25.48 
1 10/17/2005 Upside down 210.59 119.79 51.81 25.03 214.60 122.36 51.93 25.51 
1 10/26/2005 Standard 211.49 119.97 51.34 24.92 213.13 121.49 51.63 25.14 
1 11/14/2005 Standard 211.85 120.03 51.36 24.91 213.56 121.80 51.68 25.07 
1 11/16/2005 Standard 210.88 119.81 51.47 24.75 213.45 121.20 51.95 25.01 
1 12/01/2005 Standard 210.16 119.32 51.41 24.64 212.48 120.80 51.69 24.88 
1 12/30/2005 Standard 211.70 119.99 51.66 24.92 213.54 121.22 52.03 25.09 
1 02/01/2006 Standard 211.99 120.45 51.69 25.24 213.86 122.38 52.16 25.67 
1 02/14/2006 Standard 211.94 120.42 51.73 25.25 213.81 122.38 52.13 25.59 
1 02/16/2006 Standard 211.18 119.80 51.66 24.84 212.82 121.70 51.80 25.28 
1 02/20/2006 Standard 210.87 119.88 51.47 25.08 212.67 121.75 51.91 25.45 
1 02/24/2006 Standard 212.52 120.61 51.83 25.17 214.24 122.19 51.98 25.63 
1 02/27/2006 Standard 210.19 119.73 51.83 24.97 212.73 121.41 52.06 25.22 
4 02/27/2006 Standard 212.23 120.08 51.77 24.27 213.36 121.52 51.92 24.83 
1 03/03/2006 Standard 210.90 119.69 51.49 24.93 212.54 121.61 51.77 25.30 
1 03/08/2006 Standard 210.40 119.55 51.30 24.87 212.18 121.32 51.73 25.26 
1 03/17/2006 Standard 211.52 120.23 51.80 25.12 213.31 122.19 52.02 25.49 
1 03/22/2006 Standard 210.35 119.56 51.46 24.72 212.53 121.19 51.93 25.14 
1 03/30/2006 Standard 211.13 119.92 51.33 24.89 212.81 121.74 51.74 25.29 
1 04/03/2006 Standard 210.82 119.61 51.51 24.70 212.82 121.08 51.90 25.12 
1 04/27/2006 Standard 211.55 119.98 51.75 24.80 214.07 121.67 52.39 25.46 
4 05/03/2006 Standard 213.71 121.11 52.01 24.45 214.49 122.74 52.49 25.28 
4 05/16/2006 Standard 213.75 121.13 51.94 24.60 214.56 122.62 52.54 25.44 
4 06/01/2006 Standard 213.26 120.55 52.34 25.03 213.93 122.16 52.94 25.74 
4 06/15/2006 Standard 214.14 121.41 53.07 25.70 215.03 123.03 53.37 26.01 
4 06/23/2006 Standard 214.41 120.85 51.62 24.39 215.19 122.63 52.51 25.04 
  Coefficient of Variation: 0.54% 0.47% 0.07% 2.06% 0.37% 0.46% 0.83% 0.88%
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 Appendix G 
Final Post-Irradiation Calibration Curve Information for Scanner Station 1 
 
 Number 
Red Channel  
Pixel Value (C) Cni/Ci Dose (rad) 
1 
229.71  
(Mean Cni*) 1.00 0.0 
2 175.40 1.31 51.0 
3 145.41 1.58 102.0 
4 109.80 2.09 193.4 
5 108.72 2.11 199.3 
6 84.07 2.73 301.3 
7 69.86 3.29 386.8 
8 68.15 3.37 403.2 
9 60.25 3.81 495.9 
10 48.77 4.71 580.2 
11 48.82 4.71 597.9 
12 44.81 5.13 695.3 
13 40.17 5.72 773.6 
14 36.99 6.21 825.0 
15 32.29 7.11 927.0 
16 31.27 7.35 967.0 
 
Red Channel Pixel Values (Cni) 
9/6/2005-2/27/2006 
225.23 
227.69 
226.17 
227.09 
226.17 
227.45 
230.67 
226.71 
228.80 
231.61 
233.86 
234.65 
235.41 
234.48 
Coefficient of Variation: 1.6% 
*Mean Cni: 229.71 
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 Appendix H 
14-Day Post-Irradiation Calibration Curve and Information for Scanner 
Station 4 
 
Film Number 
Red Channel  
Pixel Value (C) Cni/Ci Dose (rad) 
1 227.83 1.00 0.0 
2 111.18 2.05 193.4 
3 71.08 3.21 386.8 
4 49.02 4.65 580.2 
5 38.62 5.90 773.6 
6 30.69 7.42 967.0 
7 26.71 8.53 1224.9 
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 Appendix I 
Procedure Information Sheet 
 
University of North Carolina-Chapel Hill 
Procedure Information Sheet 
           ________________ 
Medical IRB Study #:  05-RAD-358 
Title of Study: The Use of a Radiochromic Film for the Evaluation of Skin Dose during 
Extended Fluoroscopy Procedures in an Electrophysiology Lab 
Principal Investigator: James Bradford Taylor  
UNC-CH Department:  Environment, Health and Safety 
Phone Number: 919-962-5727 
           ________________ 
 
Subject Number (Corresponding to Number on Film) ________ 
 
Procedure Date ____________________ 
 
Subject Date of Birth ________________  Subject Sex (circle one)   M      F     
 
Patient Height (include units) ___________ Patient Weight (include units) ___________  
 
Patient BMI (if available) ___________________ 
 
Procedure (circle one) ABL   BIV 
 
Nature of Ablation Procedure (i.e.: atrial flutter) ____________________ 
 
Attending Physician ____________________ 
 
Assisting Fellow (if applicable) ____________________ 
 
Total Fluoroscopy Time (minutes) ____________________ 
Optional Comments: 
kVp range during procedure ____________ mA/ms range during procedure _____________ 
 
SID range during procedure _________________  Phosphor Size Used (circle one)  5   7   9 
 
Mode of Operation (i.e.: continuous, pulsed) ____________________ 
 
FILM SCANNED ON ____________________ USING SCANNER STATION ________ 
 
CALIBRATION CURVE USED:_____________RED CHANNEL VALUE __________ 
 
DOSE (RAD) ____________________ (1Gy = 100 RAD) 
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 Appendix J 
Subject, Procedure, and Scanning Information for Study Participants 
 
Subject 
Number Sex 
Height 
(inches) 
Weight 
(lbs) BMI 
Weight 
Status 
1 Male 73.0 331 43.7 Obese 
2 Male 69.0 209 30.9 Obese 
3 Male 72.0 165 22.4 Normal 
4 Male 76.0 331 40.3 Obese 
5 Female 64.0 146 25.1 Overweight
6 Male 74.0 220 28.2 Overweight
7 Male 72.0 170 23.1 Normal 
8 Male 67.0 200 31.3 Obese 
9 Female 60.0 147 28.7 Overweight
10 Male 70.0 147 21.1 Normal 
11 Male 72.0 180 24.4 Normal 
12 Female 61.0 200 37.8 Obese 
13 Male 68.0 191 29.0 Overweight
14 Male 68.5 225 33.7 Obese 
15 Female 65.0 240 39.9 Obese 
16 Female 70.0 165 23.7 Normal 
17 Female 60.0 133 26.0 Overweight
18 Female 70.0 230 33.0 Obese 
19 Male 69.0 202 29.8 Overweight
20 Male 69.5 286 41.6 Obese 
21 Male 71.0 172 24.0 Normal 
22 Female 65.0 116 19.3 Normal 
23 Female 61.0 117 22.1 Normal 
24 Male 75.0 285 35.6 Obese 
25 Male 70.0 206 29.6 Overweight
26 Male 70.0 209 30.0 Overweight
27 Male 69.5 297 43.2 Obese 
28 Male 71.0 240 33.5 Obese 
29 Male 72.0 203 27.5 Overweight
30 Female 70.0 157 22.5 Normal 
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Subject 
Number 
Procedure 
Date Procedure Nature of Diagnosis Physician 
Fluoro Time 
(minutes) 
1 09/09/2005 BIV N/A B 48.7 
2 09/14/2005 ABL AVNRT A 78.6 
3 09/15/2005 BIV N/A A 22.7 
4 10/03/2005 BIV N/A A 27.6 
5 10/03/2005 BIV N/A A 32.2 
6 11/02/2005 ABL WPWS A 91.7 
7 11/16/2005 ABL Atrial Flutter B 47.9 
8 11/18/2005 ABL WPWS B 66.4 
9 12/15/2005 BIV Upgrade A 25.8 
10 01/18/2006 BIV N/A A 19.7 
11 02/10/2006 ABL WPWS B 12.5 
12 02/17/2006 ABL AVNRT B 27.5 
13 02/22/2006 BIV N/A A 19.3 
14 03/02/2006 BIV N/A A 60.1 
15 03/08/2006 BIV N/A A 26.5 
16 03/03/2006 ABL AVNRT/WPWS B 40.7 
17 03/10/2006 ABL 
Supra Ventricular 
Tachycardia B 80.7 
18 03/17/2006 ABL 
Premature Ventricular 
Contractions B 49.1 
19 03/20/2006 BIV N/A A 29.3 
20 03/20/2006 BIV Upgrade A 40.3 
21 04/12/2006 BIV N/A A 57.1 
22 04/13/2006 ABL AVNRT B 29.1 
23 04/18/2006 ABL AVNRT B 77.0 
24 04/20/2006 BIV N/A A 71.4 
25 05/01/2006 BIV N/A A 53.4 
26 05/03/2006 BIV N/A A 25.6 
27 05/18/2006 BIV N/A A 22.4 
28 06/02/2006 ABL 
Supra Ventricular 
Tachycardia B 23.7 
29 06/06/2006 ABL Atrial Tachycardia B 85.1 
30 06/08/2006 ABL 
Left-sided Atrial 
Tachycardia A 94.0 
 
AVNRT=Atrioventricular Nodal Reentry Tachycardia  
WPWS=Wolf Parkinson White Syndrome 
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Subject 
Number 
Final Scan 
Date 
Days Post-
Irradiation 
Scan 
Station 
Lowest Red 
Channel Pixel Value 
Skin Dose 
(Rad) 
1 09/26/2005 17 1 39.50 764.4 
2 09/28/2005 14 1 69.37 366.9 
3 09/28/2005 13 1 169.93 55.8 
4 10/17/2005 14 1 109.21 175.1 
5 10/17/2005 14 1 160.78 68.1 
6 11/16/2005 14 1 86.11 264.7 
7 12/01/2005 15 1 140.20 101.3 
8 12/01/2005 13 1 113.29 163.1 
9 12/30/2005 15 1 141.70 98.6 
10 02/01/2006 14 1 170.73 54.8 
11 02/24/2006 14 1 191.40 31.8 
12 03/03/2006 14 1 140.23 101.3 
13 03/08/2006 14 1 166.63 60.1 
14 03/17/2006 15 1 91.65 239.1 
15 03/22/2006 14 1 147.77 88.0 
16 03/17/2006 14 1 165.15 62.1 
17 03/22/2006 12 1 144.87 93.0 
18 03/30/2006 13 1 115.92 155.8 
19 04/03/2006 14 1 143.24 95.8 
20 04/03/2006 14 1 80.46 294.4 
21 04/27/2006 15 1 135.19 111.0 
22 04/27/2006 14 1 186.05 37.2 
23 05/03/2006 15 4 137.02 103.6 
24 05/03/2006 13 4 97.10 210.4 
25 05/16/2006 15 4 122.27 134.9 
26 05/16/2006 13 4 182.74 38.6 
27 06/01/2006 14 4 118.71 143.6 
28 06/15/2006 13 4 156.27 71.6 
29 06/23/2006 17 4 95.16 217.8 
30 06/23/2006 15 4 142.13 94.2 
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